FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Chris Polman

Research Profile

Disorders

Concepts & Ideas

Anatomy

Physiology

Disease Progression

Procedures

Chemicals & Drugs

Phenomena

Recurrence

Co-author Network

Publications

TOP 3
Heleen Beckerman; Jiska C E Kempen; Dirk L Knol; Gustaaf J Lankhorst; Chris H Polman; Vincent de Groot
The first 10 years with multiple sclerosis: The longitudinal course of daily functioning.
Bob W van Oosten; Frederik Barkhof; Joep Killestein; Chris H Polman; Mike P Wattjes
PML in a patient treated with dimethyl fumarate from a compounding pharmacy.
Anke Vennegoor; Gertjan Wolbink; Lisanne J Balk; Frederik Barkhof; Chris H Polman; Theo Rispens; Alexandra Seewann; Eva Mm Strijbis; Bernard Mj Uitdehaag; Joep Killestein
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Chris Polman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Heleen Beckerman; Jiska C E Kempen; Dirk L Knol; Gustaaf J Lankhorst; Chris H Polman; Vincent de Groot
The first 10 years with multiple sclerosis: The longitudinal course of daily functioning.
Journal of rehabilitation medicine : official journal of the UEMS European Board of Physical and Rehabilitation Medicine 2013;45(1):68-75.
2013: Bob W van Oosten; Frederik Barkhof; Joep Killestein; Chris H Polman; Mike P Wattjes
PML in a patient treated with dimethyl fumarate from a compounding pharmacy.
The New England journal of medicine 2013;368(17):1658-9.
2013: Anke Vennegoor; Gertjan Wolbink; Lisanne J Balk; Frederik Barkhof; Chris H Polman; Theo Rispens; Alexandra Seewann; Eva Mm Strijbis; Bernard Mj Uitdehaag; Joep Killestein
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2013;19(5):593-600.
2013: Hanneke E Hulst; Chris H Polman; Petra J W Pouwels; Martijn D Steenwijk; Bernard M J Uitdehaag; Adriaan Versteeg; Hugo Vrenken; Jeroen J G Geurts; Frederik Barkhof
Cognitive impairment in MS: impact of white matter integrity, gray matter volume, and lesions.
Neurology 2013;80(11):1025-32.
2013: Eva M M Strijbis; Bernard M J Uitdehaag; Maria Vounou; Frederik Barkhof; Becky Inkster; Ludwig Kappos; Paul M Matthews; Giovanni Montana; Yvonne Naegelin; Chris H Polman; Ernst-Wilhelm Radue; Jeroen J G Geurts
Glutamate gene polymorphisms predict brain volumes in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2013;19(3):281-8.
2013: Wolter L de Graaf; Jeroen J G Geurts; Iris D Kilsdonk; Alexandra Lopez-Soriano; Peter R Luijten; Chris H Polman; Petra J W Pouwels; Fredy Visser; Frederik Barkhof; Jonas A Castelijns; Jaco J M Zwanenburg; Mike P Wattjes
Clinical application of multi-contrast 7-T MR imaging in multiple sclerosis: increased lesion detection compared to 3 T confined to grey matter.
European radiology 2013;23(2):528-40.
2013: Madeleine H Sombekke; Bernard M J Uitdehaag; Hugo Vrenken; Mike P Wattjes; Lisanne J Balk; Jessica M Nielsen; Chris H Polman; Frederik Barkhof
Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis.
Neurology 2013;80(1):69-75.
2013: Becky Inkster; Ludwig Kappos; Paul M Matthews; Giovanni Montana; Chris H Polman; Ernst-Wilhelm Radue; Eva M M Strijbis; Bernard M J Uitdehaag; Maria Vounou; Frederik Barkhof; Jeroen J G Geurts
Histone deacetylase gene variants predict brain volume changes in multiple sclerosis.
Neurobiology of aging 2013;34(1):238-47.
2013: Menno M Schoonheim; Marieke L van der Meer; Hugo Vrenken; Frederik Barkhof; Linda Douw; Jeroen J G Geurts; Doriana Landi; Chris H Polman; Cornelis J Stam
Functional connectivity changes in multiple sclerosis patients: a graph analytical study of MEG resting state data.
Human brain mapping 2013;34(1):52-61.
2012: Lisanne J Balk; Joep Killestein; Chris H Polman; Bernard M J Uitdehaag; Axel Petzold
Microcystic macular oedema confirmed, but not specific for multiple sclerosis.
Brain : a journal of neurology 2012;135(Pt 12):e226; author reply e227.
2012: Menno M Schoonheim; Hugo Vrenken; Oliver T Wiebenga; Linda Douw; Jeroen J G Geurts; Chris H Polman; Veronica Popescu; Fernanda C Rueda Lopes; Frederik Barkhof
Subcortical atrophy and cognition: sex effects in multiple sclerosis.
Neurology 2012;79(17):1754-61.
2012: Ernst-Wilhelm Radue; Krystof Selmaj; Lixin Zhang-Auberson; Catherine Agoropoulou; Pascale Burtin; Peter A Calabresi; Ana de Vera; Gordon Francis; Reinhard Hohlfeld; Frederick Holdbrook; Ludwig Kappos; Nicole Mueller-Lenke; Paul O'Connor; Chris H Polman
Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
Archives of neurology 2012;69(10):1259-69.
2012: Iris-Katharina Penner; Dirk Pleimes; Christoph Pohl; Chris H Polman; Brigitte Stemper; Frederik Barkhof; Pasquale Calabrese; Gilles Edan; Mark S Freedman; Hans-Peter Hartung; Ludwig Kappos; Vivian Lanius; David H Miller; Xavier Montalbán; Rupert Sandbrink
Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2012;18(10):1466-71.
2012: Hanneke E Hulst; Chris H Polman; Veronica Popescu; Stefan D Roosendaal; Menno M Schoonheim; Lizanne J S Schweren; Ysbrand D Van der Werf; Leo H Visser; Frederik Barkhof; Jeroen J G Geurts
Functional adaptive changes within the hippocampal memory system of patients with multiple sclerosis.
Human brain mapping 2012;33(10):2268-80.
2012: Judith M Sonder; Lidwine B Mokkink; Chris H Polman; Femke A H van der Linden; Bernard M J Uitdehaag
Validation and interpretation of the Dutch version of the Multiple Sclerosis Neuropsychological Screening Questionnaire.
Journal of the neurological sciences 2012;320(1-2):91-6.
2012: Laura J Balcer; Peter A Calabresi; Eric Eggenberger; Steven L Galetta; Chris H Polman; James V Scanlon; Annie Zhang; Robert Hyde
Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.
Journal of the neurological sciences 2012;318(1-2):119-24.
2012: Theo Rispens; Anke Vennegoor; Gert Jan Wolbink; Chris H Polman; Joep Killestein
Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.
Multiple sclerosis (Houndmills, Basingstoke, England) 2012;18(6):899-901.
2012: Jeffrey A Cohen; Chris H Polman; Stephen C Reingold; Jerry S Wolinsky
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects.
Lancet neurology 2012;11(5):467-76.
2012: Rosa E Boeschoten; Emma H Collette; Pim Cuijpers; Magdalena M Nieuwenhuis; Chris H Polman; Bernard M J Uitdehaag; Patricia van Oppen; Aartjan T F Beekman; Joost Dekker
Feasibility and outcome of a web-based self-help intervention for depressive symptoms in patients with multiple sclerosis: a pilot study.
Journal of the neurological sciences 2012;315(1-2):104-9.
2012: Lisanne J Balk; Joep Killestein; Chris H Polman; Judith M Sonder; Eva M M Strijbis; Jos W R Twisk; Bernard M J Uitdehaag; Axel Petzold
The physiological variation of the retinal nerve fiber layer thickness and macular volume in humans as assessed by spectral domain-optical coherence tomography.
Investigative ophthalmology & visual science 2012;53(3):1251-7.
2012: Ludwig Kappos; Volker Limmroth; David G MacManus; Eva Meluzinova; David H Miller; Kate Dawson; Michal Dufek; Mefkure Eraksoy; Ralf Gold; Eva Havrdova; Chris H Polman; Klaus Schmierer; Minhua Yang; Tarek A Yousry; Gilmore N O'Neill
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study.
Multiple sclerosis (Houndmills, Basingstoke, England) 2012;18(3):314-21.
2012: Libertje V A E Bosma; Dirk L Knol; J Jolijn Kragt; Chris H Polman; Bernard M J Uitdehaag
Clinical scales in progressive MS: predicting long-term disability.
Multiple sclerosis (Houndmills, Basingstoke, England) 2012;18(3):345-50.
2012: Menno M Schoonheim; Cornelis J Stam; Hugo Vrenken; Frederik Barkhof; Olga Ciccarelli; Hanneke E Hulst; Doriana Landi; Chris H Polman; Stefan D Roosendaal; Ernesto Sanz Arigita; Jeroen J G Geurts
Gender-related differences in functional connectivity in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2012;18(2):164-73.
2012: Rosa E Boeschoten; Emma H Collette; Pim Cuijpers; Joost Dekker; Chris H Polman; Bernard M J Uitdehaag; Aartjan T F Beekman; Patricia van Oppen
Internet-based self-help treatment for depression in multiple sclerosis: study protocol of a randomized controlled trial.
BMC psychiatry 2012;12():137.
2012: Martin Hardmeier; Arjan Hillebrand; Chris H Polman; Menno M Schoonheim; Frederik Barkhof; Jeroen J G Geurts; Cornelis J Stam
Cognitive dysfunction in early multiple sclerosis: altered centrality derived from resting-state functional connectivity using magneto-encephalography.
PloS one 2012;7(7):e42087.
2012: Wolter L de Graaf; Jeroen J G Geurts; Peter R Luijten; Chris H Polman; Petra J W Pouwels; Fredy Visser; Mike P Wattjes; Jaco J M Zwanenburg; Frederik Barkhof; Jonas A Castelijns
Lesion detection at seven Tesla in multiple sclerosis using magnetisation prepared 3D-FLAIR and 3D-DIR.
European radiology 2012;22(1):221-31.
2011: Joep Killestein; Richard A Rudick; Chris H Polman
Oral treatment for multiple sclerosis.
Lancet neurology 2011;10(11):1026-34.
2011: Alexandra Seewann; Paul Van Der Valk; Hugo Vrenken; Frederik Barkhof; Dirk L Knol; Evert-Jan Kooi; Chris H Polman; Petra J W Pouwels; Jeroen J G Geurts
Imaging the tip of the iceberg: visualization of cortical lesions in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2011;17(10):1202-10.
2011: Stefan D Roosendaal; Hugo Vrenken; Frederik Barkhof; Kerstin Bendfeldt; Stefan Borgwardt; Stephen L Hauser; Ludwig Kappos; Paul Matthews; Daniel Pelletier; Chris H Polman; Ernst W Radue; Jeroen J G Geurts
Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability.
Multiple sclerosis (Houndmills, Basingstoke, England) 2011;17(9):1098-106.
2011: Hans-Peter Hartung; Ludwig Kappos; Volker Knappertz; V Lanius; David H Miller; Xavier Montalbán; John Petkau; C Pohl; Chris H Polman; V Sahajpal; Rupert Sandbrink; Rick White; Frederik Barkhof; Karola Beckmann; Gilles Edan; Mark S Freedman
Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.
Neurology 2011;77(9):835-43.
2011: J Theodore Phillips; Chris H Polman; Ernie Willoughby; Paul W O'Connor; Amy Pace; William Aschenbach; Gavin Giovannoni; Robert Hyde; Fred D Lublin; Frederick E Munschauer
Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2011;17(8):970-9.
2011: Li-Fen Lee; Robert Axtell; Brigit A de Jong; Jeanette Dilley; Winston Evering; Bora Han; Joep Killestein; Kathryn Logronio; Chris H Polman; Mathias Rickert; Jing Shi; Lawrence Steinman; Guang Huan Tu; Michael G Walker; Jessica Yu; John C Lin
IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis.
Science translational medicine 2011;3(93):93ra68.
2011: M H Sombekke; N Jafari; K Bendfeldt; N Mueller-Lenke; E W Radue; Y Naegelin; Ludwig Kappos; P M Matthews; Chris H Polman; Frederik Barkhof; Rogier Q Hintzen; J J G Geurts
No influence of KIF1B on neurodegenerative markers in multiple sclerosis.
Neurology 2011;76(21):1843-5.
2011: Joep Killestein; Chris H Polman
Determinants of interferon β efficacy in patients with multiple sclerosis.
Nature reviews. Neurology 2011;7(4):221-8.
2011: Mike P Wattjes; Bob W van Oosten; Wolter L de Graaf; Alexandra Seewann; Joost C J Bot; René van den Berg; Bernard M J Uitdehaag; Chris H Polman; Frederik Barkhof
No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study.
Journal of neurology, neurosurgery, and psychiatry 2011;82(4):429-35.
2011: David G MacManus; David H Miller; Ludwig Kappos; R Gold; Eva Havrdova; Volker Limmroth; Chris H Polman; K Schmierer; Tarek A Yousry; M Eraksoy; E Meluzinova; M Dufek; M Yang; Gilmore N O'Neill; K Dawson
BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis.
Journal of neurology 2011;258(3):449-56.
2011: A Vennegoor; Mike P Wattjes; E T L van Munster; R L Kriekaart; Bob W van Oosten; Frederik Barkhof; Joep Killestein; Chris H Polman
Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.
Neurology 2011;76(6):574-6.
2011: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.
Annals of neurology 2011;69(2):292-302.
2011: Joanne H Wang; Derek Pappas; Daniel Pelletier; Chris H Polman; Sergio E Baranzini; Lori B Chibnik; Paul Iw de Bakker; Philip De Jager; David A Hafler; Stephen L Hauser; Ludwig Kappos; Paul M Matthews; Jorge R Oksenberg
Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data.
Genome medicine 2011;3(1):3.
2011: B Bodini; M Battaglini; Nicola de Stefano; Zhaleh Khaleeli; Frederik Barkhof; Declan T Chard; Massimo Filippi; Xavier Montalban; Chris H Polman; Marco Rovaris; Alex Rovira; R Samson; David Miller; Alan Thompson; Olga Ciccarelli
T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis.
Journal of neurology, neurosurgery, and psychiatry 2011;82(1):72-7.
2010: Carsten Lukas; Arjan Minneboo; Vincent de Groot; Bastiaan Moraal; Dirk L Knol; Chris H Polman; Frederik Barkhof; Hugo Vrenken
Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis.
Journal of neurology, neurosurgery, and psychiatry 2010;81(12):1351-6.
2010: V Worthington; Joep Killestein; M Judith Eikelenboom; Charlotte E Teunissen; Frederik Barkhof; Chris H Polman; B M J Uitdehaag; Axel Petzold
Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency.
Neurology 2010;75(18):1617-22.
2010: L F van der Voort; A Vennegoor; A Visser; D L Knol; B M J Uitdehaag; Frederik Barkhof; C B M Oudejans; Chris H Polman; Joep Killestein
Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS.
Neurology 2010;75(14):1228-33.
2010: I J van den Elskamp; B Boden; V Dattola; Dirk L Knol; Massimo Filippi; Ludwig Kappos; Franz Fazekas; K Wagner; Christoph Pohl; Rupert Sandbrink; Chris H Polman; B M J Uitdehaag; Frederik Barkhof
Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis.
Neuroradiology 2010;52(10):875-81.
2010: Joseph R Berger; Diego Centonze; Giancarlo Comi; Christian Confavreux; Gary R Cutter; Gavin Giovannoni; Ralf Gold; Hans-Peter Hartung; Fred Lublin; Augusto Miravalle; Xavier Montalban; Paul O'Connor; Tomas Olsson; Chris H Polman; Olaf Stuve; Jerry S Wolinsky; Tjalf Ziemssen
Considerations on discontinuing natalizumab for the treatment of multiple sclerosis.
Annals of neurology 2010;68(3):409-11.
2010: Richard A Rudick; Paul W O'Connor; Chris H Polman; AD Goodman; Soma S Ray; Nancy M Griffith; Stephanie A Jurgensen; Leonid Gorelik; Fiona Forrestal; Alfred W Sandrock; Susan E Goelz
Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.
Annals of neurology 2010;68(3):304-10.
2010: Joep Killestein; Anke Vennegoor; Eva M Strijbis; Alexandra Seewann; Bob W van Oosten; Bernard M J Uitdehaag; Chris H Polman
Natalizumab drug holiday in multiple sclerosis: poorly tolerated.
Annals of neurology 2010;68(3):392-5.
2010: Chris H Polman; Antonio Bertolotto; Florian Deisenhammer; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Joep Killestein; Henry McFarland; Joel Oger; Andrew R Pachner; John Petkau; Anthony T Reder; Stephen C Reingold; Huub Schellekens; Per Soelberg Sørensen
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.
Lancet neurology 2010;9(7):740-50.
2010: Madeleine H Sombekke; David Arteta; Mark A van de Wiel; J B A Crusius; Diego Tejedor; Joep Killestein; Antonio Martínez; A Salvador Peña; Chris H Polman; Bernard M J Uitdehaag
Analysis of multiple candidate genes in association with phenotypes of multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2010;16(6):652-9.
2010: Lisa van Winsen; J Jolijn Kragt; Erwin L J Hoogervorst; Chris H Polman; Bernard M J Uitdehaag
Outcome measurement in multiple sclerosis: detection of clinically relevant improvement.
Multiple sclerosis (Houndmills, Basingstoke, England) 2010;16(5):604-10.
2010: Chris H Polman; Richard A Rudick
The multiple sclerosis functional composite: a clinically meaningful measure of disability.
Neurology 2010;74 Suppl 3():S8-15.
2010: Robert C Axtell; Brigit A de Jong; Katia Boniface; Laura F van der Voort; Roopa Bhat; Patrizia De Sarno; Rodrigo Naves; May Han; Franklin Zhong; Jim G Castellanos; Robert Mair; Athena Christakos; Ilan Kolkowitz; Liat Katz; Joep Killestein; Chris H Polman; René de Waal Malefyt; Lawrence Steinman; Chander Raman
T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.
Nature medicine 2010;16(4):406-12.
2010: Emma C Tallantyre; Lars Bø; Omar Al-Rawashdeh; Trudy Owens; Chris H Polman; James S Lowe; Nikos Evangelou
Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2010;16(4):406-11.
2010: Laura F van der Voort; Francesca Gilli; Antonio Bertolotto; Dirk L Knol; Bernard M J Uitdehaag; Chris H Polman; Joep Killestein
Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.
Archives of neurology 2010;67(4):402-7.
2010: Lisa van Winsen; Chris H Polman; Christine D Dijkstra; Fred J H Tilders; Bernard M J Uitdehaag
Suppressive effect of glucocorticoids on TNF-alpha production is associated with their clinical effect in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2010;16(4):500-2.
2010: Mario H J Vogt; Joop ten Kate; Roosmarie J M Drent; Chris H Polman; Raymond Hupperts
Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers.
Multiple sclerosis (Houndmills, Basingstoke, England) 2010;16(4):443-9.
2009: Madeleine H Sombekke; Carsten Lukas; J B A Crusius; Diego Tejedor; Joep Killestein; David Arteta; Antonio Martínez; Bernard M J Uitdehaag; Dirk L Knol; Amado Salvador Peña; Jeroen J G Geurts; Philip L De Jager; Frederik Barkhof; Hugo Vrenken; Chris H Polman
HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis.
Archives of neurology 2009;66(12):1531-6.
2009: M Judith Eikelenboom; Joep Killestein; J Jolijn Kragt; B M J Uitdehaag; Chris H Polman
Gender differences in multiple sclerosis: cytokines and vitamin D.
Journal of the neurological sciences 2009;286(1-2):40-2.
2009: Bastiaan Moraal; Christoph Pohl; Bernard M J Uitdehaag; Chris H Polman; Gilles Edan; Mark S Freedman; Hans-Peter Hartung; Ludwig Kappos; David H Miller; Xavier Montalban; Vivian Lanius; Rupert Sandbrink; Frederik Barkhof
Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.
Archives of neurology 2009;66(11):1345-52.
2009: Ludwig Kappos; Mark S Freedman; Chris H Polman; Gilles Edan; Hans-Peter Hartung; David H Miller; Xavier Montalbán; Frederik Barkhof; Ernst W Radü; Carola Metzig; Lars Bauer; Vivian Lanius; Rupert Sandbrink; Christoph Pohl
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Lancet neurology 2009;8(11):987-97.
2009: Vincent de Groot; Heleen Beckerman; Bernard M Uitdehaag; Rogier Q Hintzen; Arjan Minneboo; Martijn W Heymans; Gustaaf J Lankhorst; Chris H Polman; Lex M Bouter
Physical and cognitive functioning after 3 years can be predicted using information from the diagnostic process in recently diagnosed multiple sclerosis.
Archives of physical medicine and rehabilitation 2009;90(9):1478-88.
2009: L F van der Voort; A Visser; Dirk L Knol; C B M Oudejans; Chris H Polman; Joep Killestein
Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2009;16(9):1049-52.
2009: Tijmen Korteweg; M Tintore; B M J Uitdehaag; Dirk L Knol; Hugo Vrenken; A Rovira; J Frederiksen; David H Miller; K Fernando; Massimo Filippi; F Agosta; M A Rocca; Franz Fazekas; C Enzinger; A Parry; Chris H Polman; Xavier Montalban; Frederik Barkhof
A search for new MRI criteria for dissemination in space in subjects with a clinically isolated syndrome.
European radiology 2009;19(9):2244-8.
2009: Richard A Rudick; Chris H Polman; Jeffrey A Cohen; M K Walton; A E Miller; Christian Confavreux; Fred D Lublin; Michael Hutchinson; P W O'Connor; S R Schwid; Laura J Balcer; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Assessing disability progression with the Multiple Sclerosis Functional Composite.
Multiple sclerosis (Houndmills, Basingstoke, England) 2009;15(8):984-97.
2009: Aran F Labrijn; Antonio Ortiz Buijsse; Ewald T J van den Bremer; Annemiek Y W Verwilligen; Wim K Bleeker; Susan J Thorpe; Joep Killestein; Chris H Polman; Rob C Aalberse; Janine Schuurman; Jan G J van de Winkel; Paul W H I Parren
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo.
Nature biotechnology 2009;27(8):767-71.
2009: Richard A Rudick; Chris H Polman
Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis.
Lancet neurology 2009;8(6):545-59.
2009: Lisa van Winsen; Laura Manenschijn; Elisabeth F C van Rossum; J Bart A Crusius; Bart A Crusius; Jan W Koper; Chris H Polman; Bernard M J Uitdehaag
A glucocorticoid receptor gene haplotype (TthIII1/ER22/23EK/9beta) is associated with a more aggressive disease course in multiple sclerosis.
The Journal of clinical endocrinology and metabolism 2009;94(6):2110-4.
2009: Sergio E Baranzini; Nicholas W Galwey; Joanne Wang; Pouya Khankhanian; Raija Lindberg; Daniel Pelletier; Wen Wu; Bernard M J Uitdehaag; Ludwig Kappos; Chris H Polman; Paul Matthews; Stephen L Hauser; Rachel A Gibson; Jorge R Oksenberg; Michael R Barnes
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis.
Human molecular genetics 2009;18(11):2078-90.
2009: Marco Rovaris; Frederik Barkhof; Massimiliano Calabrese; Nicola de Stefano; F Fazekas; David H Miller; Xavier Montalban; Chris H Polman; Maria A Rocca; Alan J Thompson; Tarek A Yousry; Massimo Filippi
MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype.
Neurology 2009;72(19):1693-701.
2009: Alexandra Seewann; Hugo Vrenken; Paul Van Der Valk; Erwin L A Blezer; Dirk L Knol; Jonas A Castelijns; Chris H Polman; Petra J W Pouwels; Frederik Barkhof; Jeroen J G Geurts
Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis.
Archives of neurology 2009;66(5):601-9.
2009: Machteld M Vellinga; Hugo Vrenken; Hanneke E Hulst; Chris H Polman; Bernard M J Uitdehaag; Petra J W Pouwels; Frederik Barkhof; Jeroen J G Geurts
Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI to demonstrate diffuse inflammation in the normal-appearing white matter (NAWM) of multiple sclerosis (MS) patients: an exploratory study.
Journal of magnetic resonance imaging : JMRI 2009;29(4):774-9.
2009: Tijmen Korteweg; Marco Rovaris; V Neacsu; Massimo Filippi; G Comi; B M Uitdehaag; Dirk L Knol; Chris H Polman; Frederik Barkhof; Hugo Vrenken
Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?
Multiple sclerosis (Houndmills, Basingstoke, England) 2009;15(4):465-71.
2009: Richard B Tenser; Chris H Polman
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment.
Neurology 2009;72(13):1191-2; author reply 1192.
2009: Michael Hutchinson; Ludwig Kappos; Peter A Calabresi; Christian Confavreux; Gavin Giovannoni; Steven L Galetta; Eva Havrdova; Fred D Lublin; David H Miller; Paul W O'Connor; J Theodore Phillips; Chris H Polman; Ernst-Wilhelm Radue; Richard A Rudick; William H Stuart; Andrzej Wajgt; Bianca Weinstock-Guttman; Daniel Wynn; Frances Lynn; Michael A Panzara
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
Journal of neurology 2009;256(3):405-15.
2009: Eva Havrdova; Steven Galetta; Michael Hutchinson; Dusan Stefoski; David Bates; Chris H Polman; Paul W O'Connor; Gavin Giovannoni; J Theodore Phillips; Fred D Lublin; Amy Pace; Richard Kim; Robert Hyde
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
Lancet neurology 2009;8(3):254-60.
2009: L F van der Voort; A Kok; A Visser; C B M Oudejans; M Caldano; F Gilli; A Bertolotto; Chris H Polman; Joep Killestein
Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
Multiple sclerosis (Houndmills, Basingstoke, England) 2009;15(2):212-8.
2009: Joep Killestein; Chris H Polman
[Alemtuzumab in early multiple sclerosis].
Nederlands tijdschrift voor geneeskunde 2009;153(1-2):46.
2009: Jessica M Nielsen; Christoph Pohl; Chris H Polman; Frederik Barkhof; Mark S Freedman; Gilles Edan; David H Miller; Lars Bauer; Rupert Sandbrink; Ludwig Kappos; Bernard M J Uitdehaag
MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome.
BMC neurology 2009;9():19.
2009: F A H van der Linden; J Jolijn Kragt; Jeremy C Hobart; Martin Klein; Alan J Thompson; Henk M van der Ploeg; Chris H Polman; Bernard M J Uitdehaag
The size of the treatment effect: do patients and proxies agree?
BMC neurology 2009;9():12.
2008: Charlotte E Teunissen; Joep Killestein; J Jolijn Kragt; Chris H Polman; Christine D Dijkstra; H J Blom
Serum homocysteine levels in relation to clinical progression in multiple sclerosis.
Journal of neurology, neurosurgery, and psychiatry 2008;79(12):1349-53.
2008: Ludwig Kappos; Ralf Gold; David H Miller; David G MacManus; Eva Havrdova; Volker Limmroth; Chris H Polman; Klaus Schmierer; Tarek A Yousry; Minhua Yang; Mefkûre Eraksoy; Eva Meluzinova; Ivan Rektor; Katherine T Dawson; Alfred W Sandrock; Gilmore N O'Neill
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Lancet 2008;372(9648):1463-72.
2008: F A H van der Linden; M B D'hooghe; G Nagels; A Van Nunen; Chris H Polman; Bernard Uitdehaag
Proxy ratings from multiple sources: disagreement on the impact of multiple sclerosis on daily life.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2008;15(9):933-9.
2008: Arjan Minneboo; jasperse bas; Frederik Barkhof; Bernard Uitdehaag; Dirk L Knol; Vincent de Groot; Chris H Polman; Jonas A Castelijns
Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters.
Journal of neurology, neurosurgery, and psychiatry 2008;79(8):917-23.
2008: Maria A Rocca; Federica Agosta; Maria Pia Sormani; Kryshani Fernando; Mar Tintorè; Tijmen Korteweg; Paola Tortorella; David H Miller; Alan Thompson; Alex Rovira; Xavier Montalban; Chris H Polman; Frederik Barkhof; Massimo Filippi
A three-year, multi-parametric MRI study in patients at presentation with CIS.
Journal of neurology 2008;255(5):683-91.
2008: J N P Zwemmer; Joost C J Bot; Brechtje Jelles; Frederik Barkhof; Chris H Polman
At the heart of primary progressive multiple sclerosis: three cases with diffuse MRI abnormalities only.
Multiple sclerosis (Houndmills, Basingstoke, England) 2008;14(3):428-30.
2008: Chris H Polman; S C Reingold; Frederik Barkhof; Peter A Calabresi; M Clanet; J A Cohen; Gary R Cutter; M S Freedman; Ludwig Kappos; F D Lublin; Henry McFarland; L M Metz; A E Miller; X Montalban; P W O'Connor; Hillel Panitch; J R Richert; J Petkau; S R Schwid; M P Sormani; A J Thompson; B G Weinshenker; Jerry Wolinsky
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment.
Neurology 2008;70(13 Pt 2):1134-40.
2008: J Jolijn Kragt; Alan J Thompson; Xavier Montalban; Mar Tintoré; J Río; Chris H Polman; Bernard Uitdehaag
Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
Neurology 2008;70(13 Pt 2):1084-91.
2008: M M Vellinga; Jonas A Castelijns; Frederik Barkhof; Bernard Uitdehaag; Chris H Polman
Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients.
Neurology 2008;70(13 Pt 2):1150-1.
2008: Machteld M Vellinga; Raoul D Oude Engberink; Alexandra Seewann; Petra J W Pouwels; Mike P Wattjes; Susanne M A van der Pol; Christiane Pering; Chris H Polman; Helga E de Vries; Jeroen J G Geurts; Frederik Barkhof
Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement.
Brain : a journal of neurology 2008;131(Pt 3):800-7.
2008: Vincent de Groot; Heleen Beckerman; Jos W Twisk; Bernard Uitdehaag; Rogier Q Hintzen; Arjan Minneboo; Gustaaf J Lankhorst; Chris H Polman; Lex M Bouter
Vitality, perceived social support and disease activity determine the performance of social roles in recently diagnosed multiple sclerosis: a longitudinal analysis.
Journal of rehabilitation medicine : official journal of the UEMS European Board of Physical and Rehabilitation Medicine 2008;40(2):151-7.
2008: Jeroen J G Geurts; Erwin L A Blezer; Hugo Vrenken; Annette van der Toorn; Jonas A Castelijns; Chris H Polman; Petra J W Pouwels; Lars Bö; Frederik Barkhof
Does high-field MR imaging improve cortical lesion detection in multiple sclerosis?
Journal of neurology 2008;255(2):183-91.
2008: C Wegner; Massimo Filippi; Tijmen Korteweg; Christian F Beckmann; Olga Ciccarelli; Nicola de Stefano; Christian Enzinger; Franz Fazekas; Federica Agosta; A Gass; J Hirsch; Heidi Johansen-Berg; L Kappos; F Barkhof; Chris H Polman; L Mancini; F Manfredonia; S Marino; D H Miller; Xavier Montalban; Jacqueline Palace; M Rocca; Stefan Ropele; A Rovira; S Smith; A Thompson; J Thornton; T Yousry; Paul Matthews
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2008;15(2):113-22.
2008: Lisa G M van Baarsen; Saskia Vosslamber; Marianne Tijssen; Josefien M C Baggen; Laura F van der Voort; Joep Killestein; Tineke C T M van der Pouw Kraan; Chris H Polman; Cornelis L Verweij
Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.
PloS one 2008;3(4):e1927.
2008: F A H van der Linden; J Jolijn Kragt; Margarethe van Bon; Martin Klein; Alan J Thompson; Henk M van der Ploeg; Chris H Polman; Bernard Uitdehaag
Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two years.
BMC neurology 2008;8():2.
2008: Chris H Polman
Early diagnosis of multiple sclerosis-still a challenge?
Multiple sclerosis (Houndmills, Basingstoke, England) 2008;14(1):2-3.
2007: jasperse bas; Hugo Vrenken; Ernesto Sanz Arigita; Vincent de Groot; Stephen Smith; Chris H Polman; Frederik Barkhof
Regional brain atrophy development is related to specific aspects of clinical dysfunction in multiple sclerosis.
NeuroImage 2007;38(3):529-37.
2007: Chris H Polman; Florian Deisenhammer; Gavin Giovannoni; Joep Killestein; Huub Schellekens
Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Neurology 2007;69(15):1553-4; author reply 1555.
2007: Peter A Calabresi; Gavin Giovannoni; Christian Confavreux; Steven L Galetta; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; Paul W O'Connor; J Theodore Phillips; Chris H Polman; Ernst-Wilhelm Radue; Richard A Rudick; William H Stuart; Fred D Lublin; Andrzej Wajgt; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
Neurology 2007;69(14):1391-403.
2007: jasperse bas; Paola Valsasina; Veronica Neacsu; Dirk L Knol; Nicola De Stefano; Christian Enzinger; Stephen Smith; Stefan Ropele; Tijmen Korteweg; Antonio Giorgio; Valerie Anderson; Chris H Polman; Massimo Filippi; David H Miller; Marco Rovaris; Frederik Barkhof; Hugo Vrenken
Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAX.
Journal of magnetic resonance imaging : JMRI 2007;26(4):881-5.
2007: Tineke Van Veen; Jessica Nielsen; Johannes Berkhof; Frederik Barkhof; Wouter Kamphorst; Lars Bö; Rivka Ravid; Cornelis L Verweij; Inge Huitinga; Chris H Polman; Bernard Uitdehaag
CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis.
Journal of neuroimmunology 2007;190(1-2):157-64.
2007: M Liedorp; E Sanchez; I M W van Hoogstraten; B Mary E von Blomberg; Frederik Barkhof; Chris H Polman; Joep Killestein
No evidence of misdiagnosis in patients with multiple sclerosis and repeated positive anticardiolipin antibody testing based on magnetic resonance imaging and long term follow-up.
Journal of neurology, neurosurgery, and psychiatry 2007;78(10):1146-8.
2007: Richard A Rudick; Deborah Miller; Steve Hass; Michael Hutchinson; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Gavin Giovannoni; Eva Havrdova; Ludwig Kappos; Fred D Lublin; David H Miller; Paul W O'Connor; J Theodore Phillips; Chris H Polman; Ernst-Wilhelm Radue; William H Stuart; Andrzej Wajgt; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara
Health-related quality of life in multiple sclerosis: effects of natalizumab.
Annals of neurology 2007;62(4):335-46.
2007: Frederik Barkhof; Chris H Polman; Ernst-Wilhelm Radue; Ludwig Kappos; Mark S Freedman; Gilles Edan; Hans-Peter Hartung; David H Miller; Xavier Montalbán; Peter A Poppe; Marlieke de Vos; Fatiha Lasri; Lars Bauer; Susanne Dahms; Klaus Wagner; Christoph Pohl; Rupert Sandbrink
Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.
Archives of neurology 2007;64(9):1292-8.
2007: Ludwig Kappos; Mark S Freedman; Chris H Polman; Gilles Edan; Hans-Peter Hartung; David H Miller; Xavier Montalbán; Frederik Barkhof; Ernst W Radü; Lars Bauer; Susanne Dahms; Vivian Lanius; Christoph Pohl; Rupert Sandbrink
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.
Lancet 2007;370(9585):389-97.
2007: Josephine K Swanton; Alex Rovira; Mar Tintore; Daniel R Altmann; Frederik Barkhof; Massimo Filippi; Elena Huerga; Katherine A Miszkiel; Gordon T Plant; Chris H Polman; Marco Rovaris; Alan J Thompson; Xavier Montalban; David H Miller
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study.
Lancet neurology 2007;6(8):677-86.
2007: Jessica M Nielsen; B Moraal; Chris H Polman; Peter A Poppe; M de Vos; Mark S Freedman; Ludwig Kappos; Frederik Barkhof; Lars Bauer; Christoph Pohl; Rupert Sandbrink; Hans-Peter Hartung; Bernard Uitdehaag
Classification of patients with a clinically isolated syndrome based on signs and symptoms is supported by magnetic resonance imaging results.
Multiple sclerosis (Houndmills, Basingstoke, England) 2007;13(6):717-21.
2007: Hugo Vrenken; Petra J W Pouwels; Stefan Ropele; Dirk L Knol; Jeroen J G Geurts; Chris H Polman; Frederik Barkhof; Jonas A Castelijns
Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of disease.
Multiple sclerosis (Houndmills, Basingstoke, England) 2007;13(6):708-16.
2007: Hans-P Hartung; Chris H Polman; Antonio Bertolotto; Florian Deisenhammer; Gavin Giovannoni; Eva Havrdova; Bernhard Hemmer; Jan Hillert; Ludwig Kappos; Bernd C Kieseier; Joep Killestein; Christophe Malcus; Manuel Comabella; Andrew R Pachner; Huub Schellekens; Finn Sellebjerg; Krzysztof Selmaj; Per Soelberg Sorensen
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report.
Journal of neurology 2007;254(7):827-37.
2007: Bernard Uitdehaag; Brechtje Jelles; Joep Killestein; Bob W van Oosten; Chris H Polman
[Immunomodulatory therapy in multiple sclerosis].
Nederlands tijdschrift voor geneeskunde 2007;151(25):1435; author reply 1435-6.
2007: Nynke F Kalkers; Rob L M Strijers; M M S Jasperse; V Neacsu; Jeroen J G Geurts; Frederik Barkhof; Chris H Polman; Cornelis Stam
Motor evoked potential: a reliable and objective measure to document the functional consequences of multiple sclerosis? Relation to disability and MRI.
Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2007;118(6):1332-40.
2007: Ludwig Kappos; David Bates; Hans-Peter Hartung; Eva Havrdova; David Miller; Chris H Polman; Mads Ravnborg; Stephen L Hauser; Richard A Rudick; Howard L Weiner; Paul W O'Connor; John King; Ernst-Wilhelm Radue; Tarek A Yousry; Eugene O Major; David B Clifford
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.
Lancet neurology 2007;6(5):431-41.
2007: jasperse bas; Cornelis Jakobs; M Judith Eikelenboom; Christine D Dijkstra; Bernard Uitdehaag; Frederik Barkhof; Chris H Polman; Charlotte E Teunissen
N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry.
Journal of neurology 2007;254(5):631-7.
2007: Lisa van Winsen; Tineke Van Veen; Elisabeth F C van Rossum; Jan W Koper; Frederik Barkhof; Chris H Polman; Bernard Uitdehaag
Glucocorticoid receptor gene polymorphisms associated with more aggressive disease phenotype in MS.
Journal of neuroimmunology 2007;186(1-2):150-5.
2007: David H Miller; Derek Soon; Kryshani T M Fernando; David G MacManus; Gareth Barker; Tarek A Yousry; Elizabeth Fisher; Paul W O'Connor; J Theodore Phillips; Chris H Polman; Ludwig Kappos; Michael Hutchinson; Eva Havrdova; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Richard A Rudick; Frances Lynn; Michael A Panzara; Alfred W Sandrock
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.
Neurology 2007;68(17):1390-401.
2007: Laura J Balcer; Steven L Galetta; Peter A Calabresi; Christian Confavreux; Gavin Giovannoni; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; David H Miller; Paul W O'Connor; J Theodore Phillips; Chris H Polman; Ernst-Wilhelm Radue; Richard A Rudick; William H Stuart; Andrzej Wajgt; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.
Neurology 2007;68(16):1299-304.
2007: Jessica M Nielsen; Tijmen Korteweg; Chris H Polman
Diagnosing MS: recent guidelines and future goals focusing on magnetic resonance imaging.
International MS journal / MS Forum 2007;14(1):29-34.
2007: Derek Soon; Daniel R Altmann; Kryshani T M Fernando; Gavin Giovannoni; Frederick Barkhof; Chris H Polman; Paul O'Connor; Bruce Gray; Michael A Panzara; David H Miller
A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis.
Journal of neurology 2007;254(3):306-14.
2007: jasperse bas; Arjan Minneboo; Vincent de Groot; Nynke F Kalkers; Paul E van Helden; Bernard Uitdehaag; Frederik Barkhof; Chris H Polman
Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis.
Archives of neurology 2007;64(2):190-4.
2007: Jens Kuhle; Christoph Pohl; Matthias Mehling; Gilles Edan; Mark S Freedman; Hans-Peter Hartung; Chris H Polman; David H Miller; Xavier Montalban; Frederik Barkhof; Lars Bauer; Susanne Dahms; Raija L P Lindberg; Ludwig Kappos; Rupert Sandbrink
Lack of association between antimyelin antibodies and progression to multiple sclerosis.
The New England journal of medicine 2007;356(4):371-8.
2007: Lars Bö; Jeroen J G Geurts; Paul Van Der Valk; Chris H Polman; Frederik Barkhof
Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis.
Archives of neurology 2007;64(1):76-80.
2007: Tijmen Korteweg; Bernard Uitdehaag; Dirk L Knol; Robin H M Smithuis; Paul R Algra; Cees de Vries; Peter A Poppe; Jan-Hein T M van Waesberghe; Elisabeth Bergers; Geert Lycklama à Nijeholt; Chris H Polman; Frederik Barkhof
Interobserver agreement on the radiological criteria of the International Panel on the diagnosis of multiple sclerosis.
European radiology 2007;17(1):67-71.
2006: J Jolijn Kragt; I M Nielsen; F A H van der Linden; Bernard Uitdehaag; Chris H Polman
How similar are commonly combined criteria for EDSS progression in multiple sclerosis?
Multiple sclerosis (Houndmills, Basingstoke, England) 2006;12(6):782-6.
2006: R H C Lazeron; Leo De Sonneville; Philip scheltens; Chris H Polman; Frederik Barkhof
Cognitive slowing in multiple sclerosis is strongly associated with brain volume reduction.
Multiple sclerosis (Houndmills, Basingstoke, England) 2006;12(6):760-8.
2006: Luba Lopatinskaya; J Zwemmer; Bernard Uitdehaag; K Lucas; Chris H Polman; Lex Nagelkerken
Mediators of apoptosis Fas and FasL predict disability progression in multiple sclerosis over a period of 10 years.
Multiple sclerosis (Houndmills, Basingstoke, England) 2006;12(6):704-9.
2006: J Theodore Phillips; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; Chris H Polman; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Infusion-related hypersensitivity reactions during natalizumab treatment.
Neurology 2006;67(9):1717-8.
2006: Ludwig Kappos; Chris H Polman; Mark S Freedman; Gilles Edan; H P Hartung; David H Miller; Xavier Montalban; Frederik Barkhof; L Bauer; Peter Jakobs; C Pohl; Rupert Sandbrink
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
Neurology 2006;67(7):1242-9.
2006: J Jolijn Kragt; F A H van der Linden; Jessica M Nielsen; Bernard Uitdehaag; Chris H Polman
Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2006;12(5):594-8.
2006: J N P Zwemmer; J Berkhof; Jonas A Castelijns; Frederik Barkhof; Chris H Polman; Bernard Uitdehaag
Classification of multiple sclerosis patients by latent class analysis of magnetic resonance imaging characteristics.
Multiple sclerosis (Houndmills, Basingstoke, England) 2006;12(5):565-72.
2006: Hugo Vrenken; Jeroen J G Geurts; Dirk L Knol; Chris H Polman; Jonas A Castelijns; Petra J W Pouwels; Frederik Barkhof
Normal-appearing white matter changes vary with distance to lesions in multiple sclerosis.
AJNR. American journal of neuroradiology 2006;27(9):2005-11.
2006: Arnaud Charil; Tarek A Yousry; Marco Rovaris; Frederik Barkhof; Nicola de Stefano; Franz Fazekas; David H Miller; Xavier Montalban; Jack H Simon; Chris H Polman; Massimo Filippi
MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation".
Lancet neurology 2006;5(10):841-52.
2006: Vincent de Groot; Heleen Beckerman; Bernard Uitdehaag; Henrica C W de Vet; Gustaaf J Lankhorst; Chris H Polman; Lex M Bouter
The usefulness of evaluative outcome measures in patients with multiple sclerosis.
Brain : a journal of neurology 2006;129(Pt 10):2648-59.
2006: F A H van der Linden; J Jolijn Kragt; Jeremy C Hobart; Martin Klein; Alan J Thompson; Henk M van der Ploeg; Chris H Polman; Bernard Uitdehaag
Proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of multiple sclerosis in daily life.
Journal of neurology, neurosurgery, and psychiatry 2006;77(10):1157-62.
2006: Ludwig Kappos; Jack Antel; Giancarlo Comi; Xavier Montalban; Paul O'Connor; Chris H Polman; Tomas Haas; Alexander A Korn; Goeril Karlsson; Ernst-Wilhelm Radue
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
The New England journal of medicine 2006;355(11):1124-40.
2006: Gisela Kobelt; Jenny Berg; Peter Lindgren; Bert Anten; Mattias Ekman; Peter J H Jongen; Chris H Polman; Bernard Uitdehaag
Costs and quality of life in multiple sclerosis in The Netherlands.
The European journal of health economics : HEPAC : health economics in prevention and care 2006;7 Suppl 2():S55-64.
2006: Hugo Vrenken; Jeroen J G Geurts; Dirk L Knol; L Noor van Dijk; Vincenzo Dattola; jasperse bas; Ronald A van Schijndel; Chris H Polman; Jonas A Castelijns; Frederik Barkhof; Petra J W Pouwels
Whole-brain T1 mapping in multiple sclerosis: global changes of normal-appearing gray and white matter.
Radiology 2006;240(3):811-20.
2006: Lisa G M van Baarsen; Tineke C T M van der Pouw Kraan; J Jolijn Kragt; J M C Baggen; François Rustenburg; T Hooper; Jan F Meilof; Michael Fero; Christine D Dijkstra; Chris H Polman; Cornelis L Verweij
A subtype of multiple sclerosis defined by an activated immune defense program.
Genes and immunity 2006;7(6):522-31.
2006: Esther C W Breij; Priscilla Heijnen; Annette van der Goes; Charlotte E Teunissen; Chris H Polman; Christine D Dijkstra
Myelin flow cytometry assay detects enhanced levels of antibodies to human whole myelin in a subpopulation of multiple sclerosis patients.
Journal of neuroimmunology 2006;176(1-2):106-14.
2006: Stephan C J Huijbregts; Nynke F Kalkers; Leo De Sonneville; Vincent de Groot; Chris H Polman
Cognitive impairment and decline in different MS subtypes.
Journal of the neurological sciences 2006;245(1-2):187-94.
2006: Axel Petzold; M I Eikelenboom; Geoff Keir; Chris H Polman; Bernard Uitdehaag; Edward J Thompson; Gavin Giovannoni
The new global multiple sclerosis severity score (MSSS) correlates with axonal but not glial biomarkers.
Multiple sclerosis (Houndmills, Basingstoke, England) 2006;12(3):325-8.
2006: Johannes M van Noort; Richard Verbeek; J F Meilof; Chris H Polman; Sandra Amor
Autoantibodies against alpha B-crystallin, a candidate autoantigen in multiple sclerosis, are part of a normal human immune repertoire.
Multiple sclerosis (Houndmills, Basingstoke, England) 2006;12(3):287-93.
2006: Chris H Polman; Huub Schellekens; Joep Killestein
Neutralizing antibodies to interferon-beta may persist after cessation of therapy: what impact could they have?
Multiple sclerosis (Houndmills, Basingstoke, England) 2006;12(3):245-6.
2006: Charlotte E Teunissen; Christine D Dijkstra; jasperse bas; Frederik Barkhof; hugo vanderstichele; Eugeen Vanmechelen; Chris H Polman; Lars Bö
Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis.
Neuropathology and applied neurobiology 2006;32(3):318-31.
2006: Tineke Van Veen; Johannes Berkhof; Chris H Polman; Bernard Uitdehaag
Analysing the effect of candidate genes on complex traits: an application in multiple sclerosis.
Immunogenetics 2006;58(5-6):347-54.
2006: Jessica M Nielsen; Frederik Barkhof; Bob W van Oosten; Chris H Polman
The role of spinal cord imaging in the diagnosis of multiple sclerosis.
Nature clinical practice. Neurology 2006;2(5):283-6; quiz 287.
2006: Chris H Polman; Stephen C Reingold; Brian G Weinshenker
Reply.
Annals of neurology 2006;59(5):871.
2006: Hugo Vrenken; Petra J W Pouwels; Jeroen J G Geurts; Dirk L Knol; Chris H Polman; Frederik Barkhof; Jonas A Castelijns
Altered diffusion tensor in multiple sclerosis normal-appearing brain tissue: cortical diffusion changes seem related to clinical deterioration.
Journal of magnetic resonance imaging : JMRI 2006;23(5):628-36.
2006: Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
The New England journal of medicine 2006;354(9):899-910.
2006: Tijmen Korteweg; Mar Tintoré; Bernard Uitdehaag; Alex Rovira; Jette Frederiksen; David Miller; Kryshani T M Fernando; Massimo Filippi; Federica Agosta; Maria Rocca; Franz Fazekas; Christian Enzinger; Paul Matthews; Allyson Parry; Chris H Polman; Xavier Montalban; Frederik Barkhof
MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study.
Lancet neurology 2006;5(3):221-7.
2006: Jeroen J G Geurts; Ilona E W Reuling; Hugo Vrenken; Bernard Uitdehaag; Chris H Polman; Jonas A Castelijns; Frederik Barkhof; Petra J W Pouwels
MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis.
Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 2006;55(3):478-83.
2006: Keith S Cover; Hugo Vrenken; Jeroen J G Geurts; Bob W van Oosten; Brechtje Jelles; Chris H Polman; Cornelis Stam; Bob W van Dijk
Multiple sclerosis patients show a highly significant decrease in alpha band interhemispheric synchronization measured using MEG.
NeuroImage 2006;29(3):783-8.
2005: Vincent de Groot; Heleen Beckerman; Gustaaf J Lankhorst; Chris H Polman; Lex M Bouter
The initial course of daily functioning in multiple sclerosis: a three-year follow-up study.
Multiple sclerosis (Houndmills, Basingstoke, England) 2005;11(6):713-8.
2005: F A H van der Linden; J Jolijn Kragt; Martin Klein; Henk M van der Ploeg; Chris H Polman; Bernard Uitdehaag
Psychometric evaluation of the multiple sclerosis impact scale (MSIS-29) for proxy use.
Journal of neurology, neurosurgery, and psychiatry 2005;76(12):1677-81.
2005: Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry Wolinsky
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".
Annals of neurology 2005;58(6):840-6.
2005: SJ Camp; Valerie L Stevenson; Alan J Thompson; Gordon T Ingle; David H Miller; C Borras; B Brochet; V Dousset; M Falautano; Massimo Filippi; Nynke F Kalkers; Xavier Montalban; Chris H Polman; DW Langdon
A longitudinal study of cognition in primary progressive multiple sclerosis.
Brain : a journal of neurology 2005;128(Pt 12):2891-8.
2005: Maria Pia Sormani; Paolo Bruzzi; Karola Beckmann; Ludwig Kappos; David H Miller; Chris H Polman; Carlo Pozzilli; Alan J Thompson; Klaus Wagner; Massimo Filippi
The distribution of magnetic resonance imaging response to interferonbeta-1b in multiple sclerosis.
Journal of neurology 2005;252(12):1455-8.
2005: Jessica M Nielsen; Tijmen Korteweg; Frederik Barkhof; Bernard Uitdehaag; Chris H Polman
Overdiagnosis of multiple sclerosis and magnetic resonance imaging criteria.
Annals of neurology 2005;58(5):781-3.
2005: R H C Lazeron; JB Boringa; M Schouten; Bernard Uitdehaag; Elisabeth Bergers; Jaap Lindeboom; M I Eikelenboom; Philip scheltens; Frederik Barkhof; Chris H Polman
Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2005;11(5):524-31.
2005: M Judith Eikelenboom; Joep Killestein; Bernard Uitdehaag; Chris H Polman
Sex differences in proinflammatory cytokine profiles of progressive patients in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2005;11(5):520-3.
2005: Lisa L M van Winsen; Tineke Van Veen; Elisabeth F C van Rossum; Chris H Polman; Timo K van den Berg; Jan W Koper; Bernard Uitdehaag
The impact of glucocorticoid receptor gene polymorphisms on glucocorticoid sensitivity is outweighted in patients with multiple sclerosis.
Journal of neuroimmunology 2005;167(1-2):150-6.
2005: Jaume Sastre-Garriga; Gordon T Ingle; Marco Rovaris; Nieves Téllez; jasperse bas; Daniel R Altmann; B Benedetti; Valerie L Stevenson; Mara Cercignani; Siobhan M Leary; Frederik Barkhof; B Brochet; V Dousset; Massimo Filippi; Xavier Montalban; Nynke F Kalkers; Chris H Polman; Alex Rovira; David H Miller; Alan J Thompson
Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data.
Neurology 2005;65(4):633-5.
2005: Arjan Minneboo; Bernard Uitdehaag; Herman J Ader; Frederik Barkhof; Chris H Polman; Jonas A Castelijns
Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients.
Neurology 2005;65(1):56-61.
2005: Jeroen J G Geurts; Petra J W Pouwels; Bernard Uitdehaag; Chris H Polman; Frederik Barkhof; Jonas A Castelijns
Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging.
Radiology 2005;236(1):254-60.
2005: Joep Killestein; Nynke F Kalkers; Chris H Polman
Glutamate inhibition in MS: the neuroprotective properties of riluzole.
Journal of the neurological sciences 2005;233(1-2):113-5.
2005: Joep Killestein; Chris H Polman
Current trials in multiple sclerosis: established evidence and future hopes.
Current opinion in neurology 2005;18(3):253-60.
2005: Peter Rieckmann; N Kruse; Lex Nagelkerken; Karola Beckmann; D Miller; Chris H Polman; Frank Dahlke; K V Toyka; H P Hartung; S Stürzebecher
Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of interferon beta-1b in patients with secondary progressive multiple sclerosis.
Journal of neurology 2005;252(5):526-33.
2005: Bernard Uitdehaag; Ludwig Kappos; Lars Bauer; Mark S Freedman; David Miller; Rupert Sandbrink; Chris H Polman
Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization.
Multiple sclerosis (Houndmills, Basingstoke, England) 2005;11(2):227-31.
2005: Tijmen Korteweg; Frederik Barkhof; Bernard Uitdehaag; Chris H Polman
How to use spinal cord magnetic resonance imaging in the McDonald diagnostic criteria for multiple sclerosis.
Annals of neurology 2005;57(4):606-7.
2005: Babs O Fabriek; J N P Zwemmer; Charlotte E Teunissen; Christine D Dijkstra; Chris H Polman; Jon D Laman; Jonas A Castelijns
In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology.
Journal of neuroimmunology 2005;161(1-2):190-4.
2005: Chris H Polman; Ludwig Kappos; Frank Dahlke; R Graf; Karola Beckmann; T Bogumil; Carlo Pozzilli; Alan J Thompson
Interferon beta-1b treatment does not induce autoantibodies.
Neurology 2005;64(6):996-1000.
2005: Chris H Polman; Frederik Barkhof; Magnhild Sandberg-Wollheim; A Linde; O Nordle; T Nederman
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
Neurology 2005;64(6):987-91.
2005: Jeroen J G Geurts; Lars Bö; Petra J W Pouwels; Jonas A Castelijns; Chris H Polman; Frederik Barkhof
Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology.
AJNR. American journal of neuroradiology 2005;26(3):572-7.
2005: Chris H Polman; Jerry Wolinsky; Stephen C Reingold
Multiple sclerosis diagnostic criteria: three years later.
Multiple sclerosis (Houndmills, Basingstoke, England) 2005;11(1):5-12.
2005: Hugo Vrenken; Frederik Barkhof; Bernard Uitdehaag; Jonas A Castelijns; Chris H Polman; Petra J W Pouwels
MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter.
Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 2005;53(2):256-66.
2005: Axel Petzold; M Judith Eikelenboom; Geoff Keir; D Grant; R H C Lazeron; Chris H Polman; Bernard Uitdehaag; Edward J Thompson; Gavin Giovannoni
Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.
Journal of neurology, neurosurgery, and psychiatry 2005;76(2):206-11.
2005: Lisa van Winsen; Daan F R Muris; Chris H Polman; Christine D Dijkstra; Timo K van den Berg; Bernard Uitdehaag
Sensitivity to glucocorticoids is decreased in relapsing remitting multiple sclerosis.
The Journal of clinical endocrinology and metabolism 2005;90(2):734-40.
2005: Charlotte E Teunissen; Martin van Boxtel; Jelle Jolles; Jan de Vente; Fred Vreeling; Frans Verhey; Chris H Polman; Christine D Dijkstra; Henk J Blom
Homocysteine in relation to cognitive performance in pathological and non-pathological conditions.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2005;43(10):1089-95.
2005: Erik J A Scherder; Erik C Wolters; Chris H Polman; Joseph Sergeant; Dick F Swaab
Pain in Parkinson's disease and multiple sclerosis: its relation to the medial and lateral pain systems.
Neuroscience and biobehavioral reviews 2005;29(7):1047-56.
2005: Charlotte E Teunissen; Christine D Dijkstra; Chris H Polman
Biological markers in CSF and blood for axonal degeneration in multiple sclerosis.
Lancet neurology 2005;4(1):32-41.
2005: M Judith Eikelenboom; Joep Killestein; Thijs Izeboud; Nynke F Kalkers; Paul A Baars; René A W van Lier; Frederik Barkhof; Bernard Uitdehaag; Chris H Polman
Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS.
Journal of neuroimmunology 2005;158(1-2):222-30.
2004: M A J Visschedijk; Bernard Uitdehaag; Martin Klein; Eleonore Van der Ploeg; E H Collette; L Vleugels; Lilian E M A Pfennings; E L J Hoogervorst; Henk M van der Ploeg; Chris H Polman
Value of health-related quality of life to predict disability course in multiple sclerosis.
Neurology 2004;63(11):2046-50.
2004: Mariëlle A J Visschedijk; Emma H Collette; Chris H Polman; Lilian E M A Pfennings; Henk M van der Ploeg
Development of a cognitive behavioral group intervention programme for patients with multiple sclerosis: an exploratory study.
Psychological reports 2004;95(3 Pt 1):735-46.
2004: Joep Killestein; PM Bet; Andre C D van Loenen; Chris H Polman
[Medicinal cannabis for diseases of the nervous system: no convincing evidence of effectiveness].
Nederlands tijdschrift voor geneeskunde 2004;148(48):2374-8.
2004: Ludwig Kappos; B Weinshenker; Carlo Pozzilli; Alan J Thompson; Frank Dahlke; Karola Beckmann; Chris H Polman; Henry McFarland
Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials.
Neurology 2004;63(10):1779-87.
2004: J Jolijn Kragt; E L J Hoogervorst; Bernard Uitdehaag; Chris H Polman
Relation between objective and subjective measures of bladder dysfunction in multiple sclerosis.
Neurology 2004;63(9):1716-8.
2004: Joost C J Bot; Erwin L A Blezer; Wouter Kamphorst; Geert J Lycklama a Nijeholt; Herman J Ader; Jonas A Castelijns; Klaas Nicolay Ig; Elisabeth Bergers; Rivka Ravid; Chris H Polman; Frederik Barkhof
The spinal cord in multiple sclerosis: relationship of high-spatial-resolution quantitative MR imaging findings to histopathologic results.
Radiology 2004;233(2):531-40.
2004: Konrad Rejdak; M Judith Eikelenboom; Axel Petzold; Edward J Thompson; Z Stelmasiak; R H C Lazeron; Frederik Barkhof; Chris H Polman; Bernard Uitdehaag; Gavin Giovannoni
CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis.
Neurology 2004;63(8):1439-45.
2004: E L J Hoogervorst; J N P Zwemmer; Brechtje Jelles; Chris H Polman; Bernard Uitdehaag
Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability.
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(5):569-74.
2004: R H C Lazeron; Serge A R B Rombouts; Philip scheltens; Chris H Polman; Frederik Barkhof
An fMRI study of planning-related brain activity in patients with moderately advanced multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(5):549-55.
2004: Mario H J Vogt; Sarah Floris; Joep Killestein; Dirk L Knol; Monique Smits; Frederik Barkhof; Chris H Polman; Lex Nagelkerken
Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients.
Journal of neuroimmunology 2004;155(1-2):155-60.
2004: Hans M Schrijver; J B A Crusius; M Asunçion García-González; Chris H Polman; Amado Salvador Peña; Frederik Barkhof; Bernard Uitdehaag
Gender-related association between the TGFB1+869 polymorphism and multiple sclerosis.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2004;24(9):536-42.
2004: Jeroen J G Geurts; Frederik Barkhof; Jonas A Castelijns; Bernard Uitdehaag; Chris H Polman; Petra J W Pouwels
Quantitative 1H-MRS of healthy human cortex, hippocampus, and thalamus: metabolite concentrations, quantification precision, and reproducibility.
Journal of magnetic resonance imaging : JMRI 2004;20(3):366-71.
2004: Joep Killestein; Chris H Polman
The therapeutic value of cannabinoids in MS: real or imaginary?
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(4):339-40.
2004: David H Miller; Massimo Filippi; F Fazekas; J L Frederiksen; Paul Matthews; Xavier Montalban; Chris H Polman
Role of magnetic resonance imaging within diagnostic criteria for multiple sclerosis.
Annals of neurology 2004;56(2):273-8.
2004: B M VanAmerongen; Christine D Dijkstra; Paul Lips; Chris H Polman
Multiple sclerosis and vitamin D: an update.
European journal of clinical nutrition 2004;58(8):1095-109.
2004: S C J Huijbregts; Nynke F Kalkers; Leo De Sonneville; Vincent de Groot; I E W Reuling; Chris H Polman
Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS.
Neurology 2004;63(2):335-9.
2004: M Judith Eikelenboom; Joep Killestein; Bernard Uitdehaag; Chris H Polman
Opticospinal multiple sclerosis: a pathogenetically distinct form?
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(3):334-5.
2004: Bob W van Oosten; Joep Killestein; E M H Mathus-Vliegen; Chris H Polman
Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist.
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(3):330-1.
2004: J N P Zwemmer; Tineke Van Veen; Lisa van Winsen; Gerard J van Kamp; Frederik Barkhof; Chris H Polman; Bernard Uitdehaag
No major association of ApoE genotype with disease characteristics and MRI findings in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(3):272-7.
2004: Chris H Polman; Joep Killestein
Statins for the treatment of multiple sclerosis: cautious hope.
Lancet 2004;363(9421):1570.
2004: Peter de Jonge; E L J Hoogervorst; Frits J Huyse; Chris H Polman
INTERMED: a measure of biopsychosocial case complexity: one year stability in Multiple Sclerosis patients.
General hospital psychiatry 2004;26(2):147-52.
2004: Sarah Floris; Annette van der Goes; Joep Killestein; Dirk L Knol; Frederik Barkhof; Chris H Polman; Christine D Dijkstra; Helga E de Vries; Jan F Meilof
Monocyte activation and disease activity in multiple sclerosis. A longitudinal analysis of serum MRP8/14 levels.
Journal of neuroimmunology 2004;148(1-2):172-7.
2004: Arjan Minneboo; Frederick Barkhof; Chris H Polman; Bernard Uitdehaag; Dirk L Knol; Jonas A Castelijns
Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis.
Archives of neurology 2004;61(2):217-21.
2004: E L J Hoogervorst; Nynke F Kalkers; Gary R Cutter; Bernard Uitdehaag; Chris H Polman
The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite.
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(1):55-60.
2004: Chris H Polman; Jerry Wolinsky; Stephen C Reingold
Multiple sclerosis: should MR criteria for dissemination in time be less stringent.
Annals of neurology 2004;55(2):297.
2004: Joost C J Bot; Frederik Barkhof; Chris H Polman; Geert Lycklama à Nijeholt; Vincent de Groot; Elisabeth Bergers; Herman J Ader; Jonas A Castelijns
Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination.
Neurology 2004;62(2):226-33.
2004: Joep Killestein; Bernard Uitdehaag; Chris H Polman
Cannabinoids in multiple sclerosis: do they have a therapeutic role?
Drugs 2004;64(1):1-11.
2003: Ludwig Kappos; Chris H Polman; Alan J Thompson; P Duda; M Clanet; G Comi; H P Hartung; X Montalban
Towards a european network for multiple sclerosis trials (ENMST).
Multiple sclerosis (Houndmills, Basingstoke, England) 2003;9(6):627-9.
2003: Tineke Van Veen; Hans M Schrijver; Antoon Zwiers; J B A Crusius; Dirk L Knol; Nynke F Kalkers; Marja L Laine; Frederik Barkhof; Amado Salvador Peña; Chris H Polman; Bernard Uitdehaag
The interleukin-1 gene family in multiple sclerosis susceptibility and disease course.
Multiple sclerosis (Houndmills, Basingstoke, England) 2003;9(6):535-9.
2003: Marianne A A van Walderveen; Ronald A van Schijndel; Petra J W Pouwels; Chris H Polman; Frederik Barkhof
Multislice T1 relaxation time measurements in the brain using IR-EPI: reproducibility, normal values, and histogram analysis in patients with multiple sclerosis.
Journal of magnetic resonance imaging : JMRI 2003;18(6):656-64.
2003: Tineke Van Veen; Lisa van Winsen; J B A Crusius; Nynke F Kalkers; Frederik Barkhof; Amado Salvador Peña; Chris H Polman; Bernard Uitdehaag
[Alpha]B-crystallin genotype has impact on the multiple sclerosis phenotype.
Neurology 2003;61(9):1245-9.
2003: Chris H Polman; Paul H P Jansen; Cees Jansen; Bernard Uitdehaag
A rare, treatable cause of relapsing encephalopathy in an MS patient on interferon beta therapy.
Neurology 2003;61(5):719.
2003: Joep Killestein; M Judith Eikelenboom; Thijs Izeboud; Nynke F Kalkers; Herman J Adèr; Frederik Barkhof; René A W van Lier; Bernard Uitdehaag; Chris H Polman
Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MS.
Journal of neuroimmunology 2003;142(1-2):141-8.
2003: Chris H Polman; Bernard Uitdehaag
New and emerging treatment options for multiple sclerosis.
Lancet neurology 2003;2(9):563-6.
2003: Geert Lycklama; Alan Thompson; Massimo Filippi; David Miller; Chris H Polman; Franz Fazekas; Frederik Barkhof
Spinal-cord MRI in multiple sclerosis.
Lancet neurology 2003;2(9):555-62.
2003: Charlotte E Teunissen; Christine D Dijkstra; Chris H Polman; E L J Hoogervorst; Klaus Von Bergmann; Dieter Lütjohann
Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients.
Neuroscience letters 2003;347(3):159-62.
2003: Bert A 't Hart; Jack T W E Vogels; Gerwin Spijksma; Herbert P M Brok; Chris H Polman; Jan van der Greef
1H-NMR spectroscopy combined with pattern recognition analysis reveals characteristic chemical patterns in urines of MS patients and non-human primates with MS-like disease.
Journal of the neurological sciences 2003;212(1-2):21-30.
2003: Joep Killestein; Bernard Uitdehaag; Chris H Polman
Cannabinoids and immune function.
JAMA : the journal of the American Medical Association 2003;290(6):754; author reply 755.
2003: Joep Killestein; Chris H Polman
Cannabis use in multiple sclerosis: excited interest.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2003;30(3):181-2.
2003: Chris H Polman; Frederik Barkhof; Ludwig Kappos; Carlo Pozzilli; Rupert Sandbrink; Frank Dahlke; Peter Jakobs; A Lorenz
Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study.
Multiple sclerosis (Houndmills, Basingstoke, England) 2003;9(4):342-8.
2003: Frederik Barkhof; Wolfgang Bruck; Christianne J M De Groot; Elisabeth Bergers; Sandra Hulshof; Jeroen J G Geurts; Chris H Polman; Paul Van Der Valk
Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance.
Archives of neurology 2003;60(8):1073-81.
2003: Jeroen J G Geurts; G Wolswijk; Lars Bö; Paul Van Der Valk; Chris H Polman; Dirk Troost; Eleonora Aronica
Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis.
Brain : a journal of neurology 2003;126(Pt 8):1755-66.
2003: Tineke Van Veen; J B A Crusius; Lisa van Winsen; Bing Xia; Frederik Barkhof; A Salvador Peña; Chris H Polman; Bernard Uitdehaag
CTLA-4 and CD28 gene polymorphisms in susceptibility, clinical course and progression of multiple sclerosis.
Journal of neuroimmunology 2003;140(1-2):188-93.
2003: Mario H J Vogt; Luba Lopatinskaya; Monique Smits; Chris H Polman; Lex Nagelkerken
Elevated osteopontin levels in active relapsing-remitting multiple sclerosis.
Annals of neurology 2003;53(6):819-22.
2003: Luba Lopatinskaya; Anette H H van Boxel-Dezaire; Frederik Barkhof; Chris H Polman; Cornelis J Lucas; Lex Nagelkerken
The development of clinical activity in relapsing-remitting MS is associated with a decrease of FasL mRNA and an increase of Fas mRNA in peripheral blood.
Journal of neuroimmunology 2003;138(1-2):123-31.
2003: Chris H Polman; Bernard Uitdehaag; Anne-Marie Klok
Ocular comorbidity in multiple sclerosis.
Lancet 2003;361(9364):1230.
2003: Joep Killestein; E L J Hoogervorst; Marcus Reif; Bep Blauw; Monique Smits; Bernard Uitdehaag; Lex Nagelkerken; Chris H Polman
Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis.
Journal of neuroimmunology 2003;137(1-2):140-3.
2003: E L J Hoogervorst; M Judith Eikelenboom; Bernard Uitdehaag; Chris H Polman
One year changes in disability in multiple sclerosis: neurological examination compared with patient self report.
Journal of neurology, neurosurgery, and psychiatry 2003;74(4):439-42.
2003: Matilde Inglese; Jan-Hein T M van Waesberghe; Marco Rovaris; Karola Beckmann; Frederik Barkhof; D Hahn; Ludwig Kappos; David H Miller; Chris H Polman; Carlo Pozzilli; Alan J Thompson; Tarek A Yousry; Klaus Wagner; Giancarlo Comi; Massimo Filippi
The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS.
Neurology 2003;60(5):853-60.
2003: J Lechner-Scott; Ludwig Kappos; M Hofman; Chris H Polman; H Ronner; Xavier Montalban; Mar Tintore; M Frontoni; C Buttinelli; Maria Pia Amato; Maria Letizia Bartolozzi; Mark Versavel; F Dahlke; J-F Kapp; R Gibberd
Can the Expanded Disability Status Scale be assessed by telephone?
Multiple sclerosis (Houndmills, Basingstoke, England) 2003;9(2):154-9.
2003: Graziella Filippini; Luca M Munari; Barbara Incorvaia; George C Ebers; Chris H Polman; Roberto D'Amico; G P A Rice
Interferons in relapsing remitting multiple sclerosis: a systematic review.
Lancet 2003;361(9357):545-52.
2003: M Judith Eikelenboom; Axel Petzold; R H C Lazeron; E Silber; Moad K Sharief; Edward J Thompson; Frederik Barkhof; Gavin Giovannoni; Chris H Polman; Bernard Uitdehaag
Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy.
Neurology 2003;60(2):219-23.
2003: Chris H Polman; Ludwig Kappos; Rick White; Frank Dahlke; Karola Beckmann; Carlo Pozzilli; A Thompson; John Petkau; D Miller
Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b.
Neurology 2003;60(1):37-43.
2003: E L J Hoogervorst; Peter de Jonge; Brechtje Jelles; Frits J Huyse; I Heeres; Henk M van der Ploeg; Bernard Uitdehaag; Chris H Polman
The INTERMED: a screening instrument to identify multiple sclerosis patients in need of multidisciplinary treatment.
Journal of neurology, neurosurgery, and psychiatry 2003;74(1):20-4.
2002: Elisabeth Bergers; Joost C J Bot; Christianne J M De Groot; Chris H Polman; Geert Lycklama à Nijeholt; Jonas A Castelijns; Paul Van Der Valk; Frederik Barkhof
Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions.
Neurology 2002;59(11):1766-71.
2002: Nynke F Kalkers; Frederik Barkhof; Elisabeth Bergers; Ronald A van Schijndel; Chris H Polman
The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study.
Multiple sclerosis (Houndmills, Basingstoke, England) 2002;8(6):532-3.
2002: M Judith Eikelenboom; Joep Killestein; Thijs Izeboud; Nynke F Kalkers; René A W van Lier; Frederik Barkhof; Bernard Uitdehaag; Chris H Polman
Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis.
Journal of neuroimmunology 2002;133(1-2):225-32.
2002: Joep Killestein; Rogier Q Hintzen; Bernard Uitdehaag; Paul A Baars; Marijke Th L Roos; René A W van Lier; Chris H Polman
Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-beta.
Journal of neuroimmunology 2002;133(1-2):217-24.
2002: Nynke F Kalkers; Najim Ameziane; Joost C J Bot; Arjan Minneboo; Chris H Polman; Frederik Barkhof
Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype.
Archives of neurology 2002;59(10):1572-6.
2002: E L J Hoogervorst; Chris H Polman; Frederik Barkhof
Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone.
Multiple sclerosis (Houndmills, Basingstoke, England) 2002;8(5):415-9.
2002: Nynke F Kalkers; Hugo Vrenken; Bernard Uitdehaag; Chris H Polman; Frederik Barkhof
Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue.
Multiple sclerosis (Houndmills, Basingstoke, England) 2002;8(5):410-4.
2002: Bernard Uitdehaag; Herman J Adèr; T J A Roosma; Vincent de Groot; Nynke F Kalkers; Chris H Polman
Multiple sclerosis functional composite: impact of reference population and interpretation of changes.
Multiple sclerosis (Houndmills, Basingstoke, England) 2002;8(5):366-71.
2002: Brigit A de Jong; Tom W J Huizinga; Eric Zanelli; Marius J Giphart; E L E M Bollen; Bernard Uitdehaag; Chris H Polman; Rudi G J Westendorp
Evidence for additional genetic risk indicators of relapse-onset MS within the HLA region.
Neurology 2002;59(4):549-55.
2002: Tineke Van Veen; Nynke F Kalkers; J B A Crusius; Lisa van Winsen; Frederik Barkhof; Peter J H Jongen; Amado Salvador Peña; Chris H Polman; Bernard Uitdehaag
The FAS-670 polymorphism influences susceptibility to multiple sclerosis.
Journal of neuroimmunology 2002;128(1-2):95-100.
2002: Axel Petzold; M Judith Eikelenboom; Djordje Gveric; Geoff Keir; M Chapman; R H C Lazeron; M Louise Cuzner; Chris H Polman; Bernard Uitdehaag; Edward J Thompson; Gavin Giovannoni
Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations.
Brain : a journal of neurology 2002;125(Pt 7):1462-73.
2002: Joep Killestein; E L J Hoogervorst; Marcus Reif; Nynke F Kalkers; Andre C D van Loenen; P G M Staats; Robert W Gorter; Bernard Uitdehaag; Chris H Polman
Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
Neurology 2002;58(9):1404-7.
2002: Elisabeth Bergers; Joost C J Bot; Paul Van Der Valk; Jonas A Castelijns; Geert J Lycklama a Nijeholt; Wouter Kamphorst; Chris H Polman; Erwin L A Blezer; Klaas Nicolay; Rivka Ravid; Frederik Barkhof
Diffuse signal abnormalities in the spinal cord in multiple sclerosis: direct postmortem in situ magnetic resonance imaging correlated with in vitro high-resolution magnetic resonance imaging and histopathology.
Annals of neurology 2002;51(5):652-6.
2002: Brigit A de Jong; Tom W J Huizinga; E L E M Bollen; Bernard Uitdehaag; Gerlof P Th Bosma; Mark A Van Buchem; Edmond J Remarque; Alexandra C S Burgmans; Nynke F Kalkers; Chris H Polman; Rudi G J Westendorp
Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis.
Journal of neuroimmunology 2002;126(1-2):172-9.
2002: Joep Killestein; Martijn Rep; Jan F Meilof; Herman J Adèr; Bernard Uitdehaag; Frederik Barkhof; René A W van Lier; Chris H Polman
Seasonal variation in immune measurements and MRI markers of disease activity in MS.
Neurology 2002;58(7):1077-80.
2002: Gordon T Ingle; Valerie L Stevenson; David H Miller; Siobhan M Leary; Marco Rovaris; Frederik Barkhof; B Brochet; V Dousset; Massimo Filippi; Xavier Montalban; Nynke F Kalkers; Chris H Polman; Alex Rovira; Alan J Thompson
Two-year follow-up study of primary and transitional progressive multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2002;8(2):108-14.
2002: Joost C J Bot; Frederik Barkhof; Geert Lycklama à Nijeholt; Dirkjan van Schaardenburg; Alexandre E Voskuyl; Herman J Ader; Jolanda A L Pijnenburg; Chris H Polman; Bernard Uitdehaag; E G J Vermeulen; Jonas A Castelijns
Differentiation of multiple sclerosis from other inflammatory disorders and cerebrovascular disease: value of spinal MR imaging.
Radiology 2002;223(1):46-56.
2002: Joep Killestein; Tomas Olsson; Erik Wallström; Anders Svenningsson; Mohsen Khademi; Lance D Blumhardt; Jan Fagius; Jan Hillert; Anne-Marie Landtblom; Charlotte Edenius; Leopold Arfors; Frederik Barkhof; Chris H Polman
Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial.
Annals of neurology 2002;51(4):467-74.
2002: Leo De Sonneville; JB Boringa; I E W Reuling; R H C Lazeron; Herman J Adèr; Chris H Polman
Information processing characteristics in subtypes of multiple sclerosis.
Neuropsychologia 2002;40(11):1751-65.
2002: E L J Hoogervorst; Nynke F Kalkers; Bernard Uitdehaag; Chris H Polman
A study validating changes in the multiple sclerosis functional composite.
Archives of neurology 2002;59(1):113-6.
2001: PD Molyneux; Gareth Barker; Frederik Barkhof; Karola Beckmann; Frank Dahlke; Massimo Filippi; M Ghazi; D Hahn; David G MacManus; Chris H Polman; Carlo Pozzilli; Ludwig Kappos; Alan J Thompson; Klaus Wagner; Tarek A Yousry; David H Miller
Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS.
Neurology 2001;57(12):2191-7.
2001: Peter A Brex; PD Molyneux; P Smiddy; Frederik Barkhof; Massimo Filippi; Tarek A Yousry; D Hahn; Y Rolland; O Salonen; Carlo Pozzilli; Chris H Polman; Alan J Thompson; Ludwig Kappos; David H Miller
The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS.
Neurology 2001;57(12):2185-90.
2001: Ludwig Kappos; Chris H Polman; Carlo Pozzilli; A Thompson; Karola Beckmann; Frank Dahlke
Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS.
Neurology 2001;57(11):1969-75.
2001: Jennifer A Freeman; Alan J Thompson; Ray Fitzpatrick; Michael Hutchinson; C Miltenburger; Karola Beckmann; Frank Dahlke; Ludwig Kappos; Chris H Polman; Carlo Pozzilli
Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life.
Neurology 2001;57(10):1870-5.
2001: Anette H H van Boxel-Dezaire; Monique Smits; S C van Trigt-Hoff; Joep Killestein; Johannes C van Houwelingen; Chris H Polman; Lex Nagelkerken
Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis.
Journal of neuroimmunology 2001;120(1-2):152-60.
2001: Nynke F Kalkers; Elisabeth Bergers; Jonas A Castelijns; Marianne A A van Walderveen; Joost C J Bot; Herman J Adèr; Chris H Polman; Frederik Barkhof
Optimizing the association between disability and biological markers in MS.
Neurology 2001;57(7):1253-8.
2001: E L J Hoogervorst; Nynke F Kalkers; Bernard Uitdehaag; Chris H Polman
Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2001;7(5):335-9.
2001: Joep Killestein; Nynke F Kalkers; Jan F Meilof; Frederik Barkhof; René A W van Lier; Chris H Polman
TNFalpha production by CD4(+) T cells predicts long-term increase in lesion load on MRI in MS.
Neurology 2001;57(6):1129-31.
2001: Joep Killestein; Martijn Rep; Frederik Barkhof; Marijke Th L Roos; Herman J Adèr; René A W van Lier; Chris H Polman
Active MRI lesion appearance in MS patients is preceded by fluctuations in circulating T-helper 1 and 2 cells.
Journal of neuroimmunology 2001;118(2):286-94.
2001: M A van der Bruggen; H B Huisman; Heleen Beckerman; Frits W Bertelsmann; Chris H Polman; Gustaaf J Lankhorst
Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury.
Journal of neurology 2001;248(8):665-71.
2001: JB Boringa; R H C Lazeron; I E W Reuling; Herman J Adèr; Lilian E M A Pfennings; Jaap Lindeboom; Leo De Sonneville; Nynke F Kalkers; Chris H Polman
The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice.
Multiple sclerosis (Houndmills, Basingstoke, England) 2001;7(4):263-7.
2001: Tineke Van Veen; J B Crusius; Hans M Schrijver; G Bouma; Joep Killestein; Lisa van Winsen; A Salvador Peña; Chris H Polman; Bernard Uitdehaag
Interleukin-12p40 genotype plays a role in the susceptibility to multiple sclerosis.
Annals of neurology 2001;50(2):275.
2001: Christianne J M De Groot; Elisabeth Bergers; Wouter Kamphorst; Rivka Ravid; Chris H Polman; Frederik Barkhof; Paul Van Der Valk
Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions.
Brain : a journal of neurology 2001;124(Pt 8):1635-45.
2001: W I McDonald; Alastair Compston; Gilles Edan; Donald Goodkin; Hans-Peter Hartung; Fred D Lublin; Henry McFarland; D W Paty; Chris H Polman; Stephen C Reingold; Magnhild Sandberg-Wollheim; William A Sibley; A Thompson; S van Den Noort; B Y Weinshenker; Jerry Wolinsky
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.
Annals of neurology 2001;50(1):121-7.
2001: Frederik Barkhof; Jan-Hein T M van Waesberghe; Massimo Filippi; Tarek A Yousry; David H Miller; D Hahn; Alan J Thompson; Ludwig Kappos; P Brex; Carlo Pozzilli; Chris H Polman
T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.
Brain : a journal of neurology 2001;124(Pt 7):1396-402.
2001: Joep Killestein; B F Den Drijver; W L Van der Graaff; Bernard Uitdehaag; Chris H Polman; René A W van Lier
Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease.
Multiple sclerosis (Houndmills, Basingstoke, England) 2001;7(3):145-50.
2001: E L J Hoogervorst; Lisa van Winsen; M Judith Eikelenboom; Nynke F Kalkers; Bernard Uitdehaag; Chris H Polman
Comparisons of patient self-report, neurologic examination, and functional impairment in MS.
Neurology 2001;56(7):934-7.
2001: S A Morré; J van Beek; Christianne J M De Groot; Joep Killestein; C J Meijer; Chris H Polman; Paul Van Der Valk; Jaap Middeldorp; A J van Den Brule
Is Epstein-Barr virus present in the CNS of patients with MS?
Neurology 2001;56(5):692.
2001: Bernard Uitdehaag; Karin Hoekstra; Jan W Koper; Chris H Polman; Christine D Dijkstra
IFN-beta1b augments glucocorticoid-induced suppression of tumor necrosis factor-alpha production by increasing the number of glucocorticoid receptors on a human monocytic cell line.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2001;21(3):133-5.
2001: Nynke F Kalkers; Rogier Q Hintzen; Jan-Hein T M van Waesberghe; R H C Lazeron; Ronald A van Schijndel; Herman J Adèr; Chris H Polman; Frederik Barkhof
Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy.
Journal of the neurological sciences 2001;184(2):155-62.
2001: Nynke F Kalkers; L Bergers; Vincent de Groot; R H C Lazeron; Marianne A A van Walderveen; Bernard Uitdehaag; Chris H Polman; Frederik Barkhof
Concurrent validity of the MS Functional Composite using MRI as a biological disease marker.
Neurology 2001;56(2):215-9.
2001: G P A Rice; Barbara Incorvaia; Luca M Munari; George C Ebers; Chris H Polman; Roberto D'Amico; G Filippini
Interferon in relapsing-remitting multiple sclerosis.
Cochrane database of systematic reviews (Online) 2001;(4):CD002002.
2001: Marianne A A van Walderveen; Geert J Lycklama a Nijeholt; Herman J Adèr; Peter J H Jongen; Chris H Polman; Jonas A Castelijns; Frederik Barkhof
Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis.
Archives of neurology 2001;58(1):76-81.
2001: G J Nijeholt; Elisabeth Bergers; Wouter Kamphorst; Joost C J Bot; Klaas Nicolay; Jonas A Castelijns; Jan-Hein T M van Waesberghe; Rivka Ravid; Chris H Polman; Frederik Barkhof
Post-mortem high-resolution MRI of the spinal cord in multiple sclerosis: a correlative study with conventional MRI, histopathology and clinical phenotype.
Brain : a journal of neurology 2001;124(Pt 1):154-66.
2000: PD Molyneux; Ludwig Kappos; Chris H Polman; Carlo Pozzilli; Frederik Barkhof; Massimo Filippi; Tarek A Yousry; D Hahn; Klaus Wagner; M Ghazi; Karola Beckmann; Frank Dahlke; N Losseff; Gareth Barker; Alan J Thompson; David H Miller
The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.
Brain : a journal of neurology 2000;123 ( Pt 11)():2256-63.
2000: J H Arnoldus; Joep Killestein; Lilian E M A Pfennings; Brechtje Jelles; Bernard Uitdehaag; Chris H Polman
Quality of life during the first 6 months of interferon-beta treatment in patients with MS.
Multiple sclerosis (Houndmills, Basingstoke, England) 2000;6(5):338-42.
2000: Brigit A de Jong; Hans M Schrijver; Tom W J Huizinga; E L E M Bollen; Chris H Polman; Bernard Uitdehaag; M C Kersbergen; A Sturk; Rudi G J Westendorp
Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis.
Annals of neurology 2000;48(4):641-6.
2000: Anette H H van Boxel-Dezaire; S C van Trigt-Hoff; Joep Killestein; Hans M Schrijver; Johannes C van Houwelingen; Chris H Polman; Lex Nagelkerken
Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?
Annals of neurology 2000;48(3):313-22.
2000: R H C Lazeron; DW Langdon; Massimo Filippi; Jan-Hein T M van Waesberghe; Valerie L Stevenson; JB Boringa; D Origgi; Alan J Thompson; M Falautano; Chris H Polman; Frederik Barkhof
Neuropsychological impairment in multiple sclerosis patients: the role of (juxta)cortical lesion on FLAIR.
Multiple sclerosis (Houndmills, Basingstoke, England) 2000;6(4):280-5.
2000: Alan J Thompson; Xavier Montalban; Frederik Barkhof; B Brochet; Massimo Filippi; David H Miller; Chris H Polman; Valerie L Stevenson; WI McDonald
Diagnostic criteria for primary progressive multiple sclerosis: a position paper.
Annals of neurology 2000;47(6):831-5.
2000: Valerie L Stevenson; David H Miller; Siobhan M Leary; Marco Rovaris; Frederik Barkhof; B Brochet; V Dousset; Massimo Filippi; R Hintzen; Xavier Montalban; Chris H Polman; Alex Rovira; J de Sa; Alan J Thompson
One year follow up study of primary and transitional progressive multiple sclerosis.
Journal of neurology, neurosurgery, and psychiatry 2000;68(6):713-8.
2000: Geert Lycklama à Nijeholt; Jonas A Castelijns; R H C Lazeron; Jan-Hein T M van Waesberghe; Chris H Polman; Bernard Uitdehaag; Frederik Barkhof
Magnetization transfer ratio of the spinal cord in multiple sclerosis: relationship to atrophy and neurologic disability.
Journal of neuroimaging : official journal of the American Society of Neuroimaging 2000;10(2):67-72.
2000: I Leng Tan; Geert Lycklama à Nijeholt; Chris H Polman; Herman J Adèr; Frederik Barkhof
Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials.
Multiple sclerosis (Houndmills, Basingstoke, England) 2000;6(2):99-104.
2000: Nynke F Kalkers; Vincent de Groot; R H C Lazeron; Joep Killestein; Herman J Adèr; Frederik Barkhof; Gustaaf J Lankhorst; Chris H Polman
MS functional composite: relation to disease phenotype and disability strata.
Neurology 2000;54(6):1233-9.
2000: Joep Killestein; Hans M Schrijver; J B Crusius; C Pérez; Bernard Uitdehaag; A S Peña; Chris H Polman
Intracellular adhesion molecule-1 polymorphisms and genetic susceptibility to multiple sclerosis: additional data and meta-analysis.
Annals of neurology 2000;47(2):277-9.
2000: Joost C J Bot; Frederik Barkhof; Geert Lycklama à Nijeholt; Elisabeth Bergers; Chris H Polman; Herman J Adèr; Jonas A Castelijns
Comparison of a conventional cardiac-triggered dual spin-echo and a fast STIR sequence in detection of spinal cord lesions in multiple sclerosis.
European radiology 2000;10(5):753-8.
2000: Geert Lycklama à Nijeholt; Bernard Uitdehaag; Elisabeth Bergers; Jonas A Castelijns; Chris H Polman; Frederik Barkhof
Spinal cord magnetic resonance imaging in suspected multiple sclerosis.
European radiology 2000;10(2):368-76.
1999: Jan-Hein T M van Waesberghe; Wouter Kamphorst; Christianne J M De Groot; Marianne A A van Walderveen; Jonas A Castelijns; Rivka Ravid; Geert Lycklama à Nijeholt; Paul Van Der Valk; Chris H Polman; Alan J Thompson; Frederik Barkhof
Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability.
Annals of neurology 1999;46(5):747-54.
1999: Lilian E M A Pfennings; Henk M van der Ploeg; Larry Cohen; Chris H Polman
A comparison of responsiveness indices in multiple sclerosis patients.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 1999;8(6):481-9.
1999: Lilian E M A Pfennings; Henk M van der Ploeg; Larry Cohen; Inge Bramsen; Chris H Polman; Gustaaf J Lankhorst; L Vleugels
A health-related quality of life questionnaire for multiple sclerosis patients.
Acta neurologica Scandinavica 1999;100(3):148-55.
1999: Lilian E M A Pfennings; Larry Cohen; D Miller; Laurent Gerbaud; L Vleugels; J Freeman; D Vernay; S Biolay; Pierre Ketelaer; A Thompson; Chris H Polman; Henk M van der Ploeg
Using the Short Form-36 with multiple sclerosis patients in five countries: a cross-cultural comparison.
Psychological reports 1999;85(1):19-31.
1999: Lilian E M A Pfennings; Larry Cohen; Herman J Adèr; Chris H Polman; Gustaaf J Lankhorst; R Smits; Henk M van der Ploeg
Exploring differences between subgroups of multiple sclerosis patients in health-related quality of life.
Journal of neurology 1999;246(7):587-91.
1999: Marianne A A van Walderveen; Frederik Barkhof; Petra J W Pouwels; Ronald A van Schijndel; Chris H Polman; Jonas A Castelijns
Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy.
Annals of neurology 1999;46(1):79-87.
1999: SJ Camp; Valerie L Stevenson; Alan J Thompson; David H Miller; C Borras; S Auriacombe; B Brochet; M Falautano; Massimo Filippi; L Hérissé-Dulo; Xavier Montalban; E Parrcira; Chris H Polman; J de Sa; DW Langdon
Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates.
Brain : a journal of neurology 1999;122 ( Pt 7)():1341-8.
1999: Anette H H van Boxel-Dezaire; S C Hoff; Bob W van Oosten; Cornelis L Verweij; A M Dräger; H J Adèr; Johannes C van Houwelingen; Frederik Barkhof; Chris H Polman; Lex Nagelkerken
Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis.
Annals of neurology 1999;45(6):695-703.
1999: Martijn Rep; H M Schrijver; T van Lopik; Rogier Q Hintzen; Marijke Th L Roos; Herman J Adèr; Chris H Polman; René A W van Lier
Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients.
Journal of neuroimmunology 1999;96(1):92-100.
1999: Valerie L Stevenson; David H Miller; Marco Rovaris; Frederik Barkhof; B Brochet; V Dousset; V Dousset; Massimo Filippi; Xavier Montalban; Chris H Polman; Alex Rovira; J de Sa; Alan J Thompson
Primary and transitional progressive MS: a clinical and MRI cross-sectional study.
Neurology 1999;52(4):839-45.
1999: Marianne A A van Walderveen; Luc Truyen; Bob W van Oosten; Jonas A Castelijns; Geert Lycklama à Nijeholt; Jan-Hein T M van Waesberghe; Chris H Polman; Frederik Barkhof
Development of hypointense lesions on T1-weighted spin-echo magnetic resonance images in multiple sclerosis: relation to inflammatory activity.
Archives of neurology 1999;56(3):345-51.
1999: Hans M Schrijver; J B A Crusius; Bernard Uitdehaag; M Asunçion García-González; Piet J Kostense; Chris H Polman; Amado Salvador Peña
Association of interleukin-1beta and interleukin-1 receptor antagonist genes with disease severity in MS.
Neurology 1999;52(3):595-9.
1999: Larry Cohen; Francois Pouwer; Lilian E M A Pfennings; Gustaaf J Lankhorst; Henk M van der Ploeg; Chris H Polman; Herman J Adèr; A Jønnson; L Vleugels
Factor structure of the Disability and Impact Profile in patients with multiple sclerosis.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 1999;8(1-2):141-50.
1999: K Nasseri; Bernard Uitdehaag; M A van Walderveen; H J Ader; Chris H Polman
Cardiovascular autonomic function in patients with relapsing remitting multiple sclerosis: a new surrogate marker of disease evolution?
European journal of neurology : the official journal of the European Federation of Neurological Societies 1999;6(1):29-33.
1998: Jan-Hein T M van Waesberghe; Mark A Van Buchem; Massimo Filippi; Jonas A Castelijns; M A Rocca; R van der Boom; Chris H Polman; Frederik Barkhof
MR outcome parameters in multiple sclerosis: comparison of surface-based thresholding segmentation and magnetization transfer ratio histographic analysis in relation to disability (a preliminary note).
AJNR. American journal of neuroradiology 1998;19(10):1857-62.
1998: Bob W van Oosten; Luc Truyen; Frederik Barkhof; Chris H Polman
Choosing drug therapy for multiple sclerosis. An update.
Drugs 1998;56(4):555-69.
1998: Lilian E M A Pfennings; Larry Cohen; Henk M van der Ploeg; Chris H Polman; Gustaaf J Lankhorst
Reliability of two measures of health-related quality of life in patients with multiple sclerosis.
Perceptual and motor skills 1998;87(1):111-4.
1998: Marianne A A van Walderveen; Frederik Barkhof; MW Tas; Chris H Polman; S T Frequin; Otto R Hommes; A J Thompson; Jakob Valk
Patterns of brain magnetic resonance abnormalities on T2-weighted spin echo images in clinical subgroups of multiple sclerosis: a large cross-sectional study.
European neurology 1998;40(2):91-8.
1998: Bob W van Oosten; Frederik Barkhof; Petra E T Scholten; B M von Blomberg; Herman J Adèr; Chris H Polman
Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis.
Archives of neurology 1998;55(6):793-8.
1998: Marianne A A van Walderveen; Wouter Kamphorst; Philip scheltens; Jan-Hein T M van Waesberghe; Rivka Ravid; Jakob Valk; Chris H Polman; Frederik Barkhof
Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis.
Neurology 1998;50(5):1282-8.
1998: G J Nijeholt; Marianne A A van Walderveen; Jonas A Castelijns; Jan-Hein T M van Waesberghe; Chris H Polman; Philip scheltens; Peter Rosier; Peter J H Jongen; Frederik Barkhof
Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms.
Brain : a journal of neurology 1998;121 ( Pt 4)():687-97.
1998: Jan-Hein T M van Waesberghe; Marianne A A van Walderveen; Jonas A Castelijns; Philip scheltens; Geert Lycklama à Nijeholt; Chris H Polman; Frederik Barkhof
Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR.
AJNR. American journal of neuroradiology 1998;19(4):675-83.
1998: Frederik Barkhof; Martin Elton; J Lindeboom; MW Tas; W F Schmidt; Otto R Hommes; Chris H Polman; A Kok; J Valk
Functional correlates of callosal atrophy in relapsing-remitting multiple sclerosis patients. A preliminary MRI study.
Journal of neurology 1998;245(3):153-8.
1998: K Nasseri; B J TenVoorde; Herman J Adèr; Bernard Uitdehaag; Chris H Polman
Longitudinal follow-up of cardiovascular reflex tests in multiple sclerosis.
Journal of the neurological sciences 1998;155(1):50-4.
1998: Geert Lycklama à Nijeholt; Jonas A Castelijns; JG Weerts; Herman J Adèr; Jan-Hein T M van Waesberghe; Chris H Polman; Frederik Barkhof
Sagittal MR of multiple sclerosis in the spinal cord: fast versus conventional spin-echo imaging.
AJNR. American journal of neuroradiology 1998;19(2):355-60.
1997: Frederik Barkhof; Jan-Hein T M van Waesberghe; Bernard Uitdehaag; Chris H Polman
Ibuprofen does not suppress active multiple sclerosis lesions on gadolinium-enhanced MR images.
Annals of neurology 1997;42(6):982.
1997: Frederik Barkhof; Massimo Filippi; David H Miller; Philip scheltens; A Campi; Chris H Polman; G Comi; Herman J Adèr; N Losseff; J Valk
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.
Brain : a journal of neurology 1997;120 ( Pt 11)():2059-69.
1997: Jan-Hein T M van Waesberghe; Jonas A Castelijns; W Roser; N Silver; Tarek A Yousry; Geert Lycklama à Nijeholt; Herman J Adèr; Bernard Uitdehaag; Ernst-Wilhelm Radue; Chris H Polman; Ludwig Kappos; David H Miller; Frederik Barkhof
Single-dose gadolinium with magnetization transfer versus triple-dose gadolinium in the MR detection of multiple sclerosis lesions.
AJNR. American journal of neuroradiology 1997;18(7):1279-85.
1997: Bob W van Oosten; Bernard Uitdehaag; Frederik Barkhof; H P Hartung; John Wagstaff; Chris H Polman
Interleukin-2 therapy does not exacerbate multiple sclerosis.
Neurology 1997;49(2):633-4.
1997: Bob W van Oosten; M Lai; S Hodgkinson; Frederik Barkhof; D H Miller; I F Moseley; Alan J Thompson; P Rudge; A McDougall; J G McLeod; Herman J Adèr; Chris H Polman
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial.
Neurology 1997;49(2):351-7.
1997: Alan J Thompson; Chris H Polman; David H Miller; WI McDonald; B Brochet; X Filippi M Montalban; J De Sá
Primary progressive multiple sclerosis.
Brain : a journal of neurology 1997;120 ( Pt 6)():1085-96.
1997: Geert Lycklama à Nijeholt; Frederik Barkhof; Philip scheltens; Jonas A Castelijns; Herman J Adèr; Jan-Hein T M van Waesberghe; Chris H Polman; S J Jongen; Jakob Valk
MR of the spinal cord in multiple sclerosis: relation to clinical subtype and disability.
AJNR. American journal of neuroradiology 1997;18(6):1041-8.
1997: Martijn Rep; Bob W van Oosten; Marijke Th L Roos; Herman J Adèr; Chris H Polman; René A W van Lier
Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans.
The Journal of clinical investigation 1997;99(9):2225-31.
1997: Frederik Barkhof; Chris H Polman
Oral or intravenous methylprednisolone for acute relapses of MS?
Lancet 1997;349(9056):893-4.
1997: Tom W J Huizinga; Rudi G J Westendorp; E L Bollen; Vivian Keijsers; BM Brinkman; JA Langermans; Ferdinand C Breedveld; Cornelis L Verweij; L van de Gaer; L Dams; J B A Crusius; A García-Gonzalez; Bob W van Oosten; Chris H Polman; A S Peña
TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients.
Journal of neuroimmunology 1997;72(2):149-53.
1997: Jan-Hein T M van Waesberghe; Jonas A Castelijns; Philip scheltens; Luc Truyen; G J Lycklana A Nijeholt; FG Hoogenraad; Chris H Polman; Jakob Valk; Frederik Barkhof
Comparison of four potential MR parameters for severe tissue destruction in multiple sclerosis lesions.
Magnetic resonance imaging 1997;15(2):155-62.
1997: Luc Truyen; Frederik Barkhof; MW Tas; Marianne A A van Walderveen; S T Frequin; Otto R Hommes; J J Nauta; Chris H Polman; J Valk
Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trials.
Multiple sclerosis (Houndmills, Basingstoke, England) 1997;2(6):283-90.
1996: Bob W van Oosten; Frederik Barkhof; Luc Truyen; J B Boringa; Frits W Bertelsmann; B M von Blomberg; J N Woody; H P Hartung; Chris H Polman
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.
Neurology 1996;47(6):1531-4.
1996: Luc Truyen; Jan-Hein T M van Waesberghe; Marianne A A van Walderveen; Bob W van Oosten; Chris H Polman; Otto R Hommes; H J Adèr; Frederik Barkhof
Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.
Neurology 1996;47(6):1469-76.
1996: Bob W van Oosten; M Lai; Frederik Barkhof; D H Miller; I F Moseley; A J Thompson; S Hodgkinson; Chris H Polman
A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 1996;1(6):339-42.
1996: Martijn Rep; R Q Hintzen; Chris H Polman; René A W van Lier
Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells.
Journal of neuroimmunology 1996;67(2):111-8.
1996: Gustaaf J Lankhorst; F Jelles; Ron Smits; Chris H Polman; Dirk J Kuik; Lilian E M A Pfennings; Larry Cohen; Henk M van der Ploeg; Pierre Ketelaer; L Vleugels
Quality of life in multiple sclerosis: the disability and impact profile (DIP).
Journal of neurology 1996;243(6):469-74.
1996: Bob W van Oosten; Martijn Rep; René A W van Lier; P E Scholten; B M von Blomberg; K W Pflughaupt; H P Hartung; H J Adèr; Chris H Polman
A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis.
Journal of neuroimmunology 1996;66(1-2):49-55.
1996: Luc Truyen; Frederik Barkhof; S T Frequin; Chris H Polman; H Tobi; Otto R Hommes; J Valk
Magnetic resonance imaging of epilepsy in multiple sclerosis: a case control study. Implications for treatment trials with 4-aminopyridine.
Multiple sclerosis (Houndmills, Basingstoke, England) 1996;1(4):213-7.
1996: Bernard Uitdehaag; Chris H Polman; K Sontrop; Christine D Dijkstra
The effect of the 21-aminosteroid U74006F on the clinical course of acute experimental allergic encephalomyelitis.
Journal of the neurological sciences 1996;135(1):18-20.
1996: Jan-Hein T M van Waesberghe; J A Castelijns; JG Weerts; G J Nijeholt; J P Hillegers; Chris H Polman; Frederik Barkhof
Disappearance of multiple sclerosis lesions with severely prolonged T1 on images obtained by a FLAIR pulse sequence.
Magnetic resonance imaging 1996;14(2):209-13.
1995: Marianne A A van Walderveen; Frederik Barkhof; Otto R Hommes; Chris H Polman; H Tobi; S T Frequin; J Valk
Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images.
Neurology 1995;45(9):1684-90.
1995: Bob W van Oosten; Luc Truyen; Frederik Barkhof; Chris H Polman
Multiple sclerosis therapy. A practical guide.
Drugs 1995;49(2):200-12.
1995: M W Tas; F Barkhol; Marianne A A van Walderveen; Chris H Polman; Otto R Hommes; J Valk
The effect of gadolinium on the sensitivity and specificity of MR in the initial diagnosis of multiple sclerosis.
AJNR. American journal of neuroradiology 1995;16(2):259-64.
1995: Chris H Polman; F Dahlke; A J Thompson; M Ghazi; L Kappos; C Miltenburger; C Pozilli
Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial.
Multiple sclerosis (Houndmills, Basingstoke, England) 1995;1 Suppl 1():S51-4.
1995: R Q Hintzen; Urszula Fiszer; Sten Fredrikson; Martijn Rep; Chris H Polman; René A W van Lier; H Link
Analysis of CD27 surface expression on T cell subsets in MS patients and control individuals.
Journal of neuroimmunology 1995;56(1):99-105.
1994: Chris H Polman; Frits W Bertelsmann; R de Waal; H A van Diemen; Bernard Uitdehaag; A C van Loenen; J C Koetsier
4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis.
Archives of neurology 1994;51(11):1136-9.
1994: Bernard Uitdehaag; Chris H Polman; Christianne J M De Groot; Christine D Dijkstra
Effect of K+ channel blockers on the clinical course and histological features of experimental allergic encephalomyelitis.
Acta neurologica Scandinavica 1994;90(4):299-301.
1994: R C Smits; H H Emmen; Frits W Bertelsmann; Beverly M Kulig; A C van Loenen; Chris H Polman
The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study.
Neurology 1994;44(9):1701-5.
1994: Martijn Rep; R Q Hintzen; Chris H Polman; René A W van Lier
Functional defects in peripheral blood T cells of multiple sclerosis patients. Diminished in vitro responsiveness in accessory cell dependent activation systems.
Journal of neuroimmunology 1994;52(2):139-46.
1994: Chris H Polman; Frits W Bertelsmann; A C van Loenen; J C Koetsier
4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety.
Archives of neurology 1994;51(3):292-6.
1994: Marianne A A van Walderveen; M W Tas; Frederik Barkhof; Chris H Polman; S T Frequin; Otto R Hommes; J Valk
Magnetic resonance evaluation of disease activity during pregnancy in multiple sclerosis.
Neurology 1994;44(2):327-9.
1994: Christine D Dijkstra; E R van der Voort; Christianne J M De Groot; I Huitinga; Bernard Uitdehaag; Chris H Polman; F Berkenbosch
Therapeutic effect of the D2-dopamine agonist bromocriptine on acute and relapsing experimental allergic encephalomyelitis.
Psychoneuroendocrinology 1994;19(2):135-42.
1993: Martin J B Taphoorn; E van Someren; Frank J Snoek; R L Strijers; Dick F Swaab; F Visscher; L P de Waal; Chris H Polman
Fatigue, sleep disturbances and circadian rhythm in multiple sclerosis.
Journal of neurology 1993;240(7):446-8.
1993: H A Van Diemen; Chris H Polman; J C Koetsier; A C Van Loenen; J J Nauta; Frits W Bertelsmann
4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety.
Clinical neuropharmacology 1993;16(3):195-204.
1993: Bernard Uitdehaag; Christianne J M De Groot; A Kreike; P H van der Meide; Chris H Polman; Christine D Dijkstra
The significance of in-situ Ia antigen expression in the pathogenesis of autoimmune central nervous system disease.
Journal of autoimmunity 1993;6(3):323-35.
1993: H A van Diemen; Chris H Polman; M M van Dongen; J J Nauta; R L Strijers; A C van Loenen; Frits W Bertelsmann; J C Koetsier
4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study.
Journal of the neurological sciences 1993;116(2):220-6.
1993: Christine D Dijkstra; Chris H Polman; F Berkenbosch
Multiple sclerosis: some possible therapeutic opportunities.
Trends in pharmacological sciences 1993;14(4):124-9.
1992: H A van Diemen; Chris H Polman; T M van Dongen; A C van Loenen; J J Nauta; Martin J B Taphoorn; H K van Walbeek; J C Koetsier
The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study.
Annals of neurology 1992;32(2):123-30.
1992: R Q Hintzen; Chris H Polman; C J Lucas; René A W van Lier
Multiple sclerosis: immunological findings and possible implications for therapy.
Journal of neuroimmunology 1992;39(1-2):1-10.
1992: Christine D Dijkstra; E R van der Voort; Christianne J M De Groot; Bernard Uitdehaag; Chris H Polman; F Berkenbosch
The therapeutic effect of bromocriptine on acute and chronic experimental allergic encephalomyelitis.
Annals of neurology 1992;31(4):450-1.
1992: H A Van Diemen; M M Van Dongen; J J Nauta; P Lanting; Chris H Polman
Pupillary light reflex latency in patients with multiple sclerosis.
Electroencephalography and clinical neurophysiology 1992;82(3):213-9.
1992: A van der Horst; P N de Goede; H A van Diemen; Chris H Polman; H J Martens
Determination of 4-aminopyridine in serum by solid-phase extraction and high-performance liquid chromatography.
Journal of chromatography 1992;574(1):166-9.
1992: H A van Diemen; P Lanting; J C Koetsier; R L Strijers; H K van Walbeek; Chris H Polman
Evaluation of the visual system in multiple sclerosis: a comparative study of diagnostic tests.
Clinical neurology and neurosurgery 1992;94(3):191-5.
1992: H A van Diemen; M M van Dongen; J W Dammers; Chris H Polman
Increased visual impairment after exercise (Uhthoff's phenomenon) in multiple sclerosis: therapeutic possibilities.
European neurology 1992;32(4):231-4.
1991: R Q Hintzen; René A W van Lier; K C Kuijpers; Paul A Baars; Wim Schaasberg; C J Lucas; Chris H Polman
Elevated levels of a soluble form of the T cell activation antigen CD27 in cerebrospinal fluid of multiple sclerosis patients.
Journal of neuroimmunology 1991;35(1-3):211-7.
1991: J R Anema; M W Heijenbrok; Th J C Faes; Jan J Heimans; P Lanting; Chris H Polman
Cardiovascular autonomic function in multiple sclerosis.
Journal of the neurological sciences 1991;104(2):129-34.
1991: Bernard Uitdehaag; Chris H Polman; Christianne J M De Groot; I Huitinga; Christine D Dijkstra
Failure of sulfasalazine to influence experimental autoimmune encephalomyelitis.
Acta neurologica Scandinavica 1991;84(2):173-4.
1991: M M van Dongen; Frits W Bertelsmann; Chris H Polman
Sensitivity of eye movement registration and visual evoked potentials in evaluation of therapy in patients with multiple sclerosis.
Journal of the neurological sciences 1991;102(1):25-31.
1991: Frederik Barkhof; Philip scheltens; J Valk; C Waalewijn; Bernard Uitdehaag; Chris H Polman
Serial quantitative MR assessment of optic neuritis in a case of neuromyelitis optica, using Gadolinium- "enhanced" STIR imaging.
Neuroradiology 1991;33(1):70-1.
1990: Chris H Polman; H A van Diemen; M M van Dongen; J C Koetsier; A C van Loenen; H K van Walbeek
4-Aminopyridine in multiple sclerosis.
Annals of neurology 1990;28(4):589.
1990: Jan J Heimans; M De Visser; Chris H Polman; J Nauta; Wouter Kamphorst; D Troost
Accuracy and interobserver variation in the interpretation of computed tomography in solitary brain lesions.
Archives of neurology 1990;47(5):520-3.
1989: Bernard Uitdehaag; Chris H Polman; J Valk; J C Koetsier; C J Lucas
Magnetic resonance imaging studies in multiple sclerosis twins.
Journal of neurology, neurosurgery, and psychiatry 1989;52(12):1417-9.
1989: I Matthaei; Chris H Polman; Christianne J M De Groot; Christine D Dijkstra; J C Koetsier; T Sminia
Observer agreement in the assessment of clinical signs in experimental allergic encephalomyelitis.
Journal of neuroimmunology 1989;23(1):25-8.
1988: Chris H Polman; I Matthaei; Christianne J M De Groot; J C Koetsier; T Sminia; Christine D Dijkstra
Low-dose cyclosporin A induces relapsing remitting experimental allergic encephalomyelitis in the Lewis rat.
Journal of neuroimmunology 1988;17(3):209-16.
1988: Christine D Dijkstra; Christianne J M De Groot; J C Koetsier; I Matthaei; Chris H Polman; T Sminia
Low-dose cyclosporin A induces relapsing experimental allergic encephalomyelitis in the Lewis rat.
Annals of the New York Academy of Sciences 1988;540():549-50.
1988: A J Breukelman; Chris H Polman; R G de Slegte; J C Koetsier
Neuromyelitis optica (Devic's syndrome): not always multiple sclerosis.
Clinical neurology and neurosurgery 1988;90(4):357-60.
1987: Chris H Polman; Christine D Dijkstra; Christianne J M De Groot; J C Koetsier; T Sminia
Presence of Ia-positive cells in the central nervous system of the rat during various pathological conditions.
International archives of allergy and applied immunology 1987;83(1):109-11.
1987: Chris H Polman; C J de Groot; J C Koetsier; T Sminia; A J Veerman
Cerebrospinal fluid cells in multiple sclerosis and other neurological diseases: an immunocytochemical study.
Journal of neurology 1987;234(1):19-22.